
<html lang="en"     class="pb-page"  data-request-id="0640eb5c-b188-4ac4-af77-0172f0c56636"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.7b00360;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-15;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors" /></meta><meta name="dc.Creator" content="Ken A.  Brameld" /></meta><meta name="dc.Creator" content="Timothy D.  Owens" /></meta><meta name="dc.Creator" content="Erik  Verner" /></meta><meta name="dc.Creator" content="Eleni  Venetsanakos" /></meta><meta name="dc.Creator" content="J. Michael  Bradshaw" /></meta><meta name="dc.Creator" content="Vernon T.  Phan" /></meta><meta name="dc.Creator" content="Danny  Tam" /></meta><meta name="dc.Creator" content="Kwan  Leung" /></meta><meta name="dc.Creator" content="Jin  Shu" /></meta><meta name="dc.Creator" content="Jacob  LaStant" /></meta><meta name="dc.Creator" content="David G.  Loughhead" /></meta><meta name="dc.Creator" content="Tony  Ton" /></meta><meta name="dc.Creator" content="Dane E.  Karr" /></meta><meta name="dc.Creator" content="Mary E.  Gerritsen" /></meta><meta name="dc.Creator" content="David M.  Goldstein" /></meta><meta name="dc.Creator" content="Jens Oliver  Funk" /></meta><meta name="dc.Description" content="Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in..." /></meta><meta name="Description" content="Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 25, 2017" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00360" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00360" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00360" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00360" /></link>
        
    
    

<title>Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00360" /></meta><meta property="og:title" content="Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0016.jpeg" /></meta><meta property="og:description" content="Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to develop an irreversible covalent inhibitor of FGFR1–4 for use in oncology indications. An irreversible covalent binding mechanism imparts many desirable pharmacological benefits including high potency, selectivity, and prolonged target inhibition. Herein we report the structure-based design, medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compound 34 (PRN1371), a highly selective and potent FGFR1–4 inhibitor." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00360"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00360">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00360&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00360&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00360&amp;href=/doi/10.1021/acs.jmedchem.7b00360" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6516-6527</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00010" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.6b01906" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ken+A.++Brameld">Ken A. Brameld</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8643-3218" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+D.++Owens">Timothy D. Owens</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erik++Verner">Erik Verner</a></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eleni++Venetsanakos">Eleni Venetsanakos</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Michael++Bradshaw">J. Michael Bradshaw</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vernon+T.++Phan">Vernon T. Phan</a></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danny++Tam">Danny Tam</a></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwan++Leung">Kwan Leung</a></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Shu">Jin Shu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacob++LaStant">Jacob LaStant</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Loughhead">David G. Loughhead</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Ton">Tony Ton</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dane+E.++Karr">Dane E. Karr</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+E.++Gerritsen">Mary E. Gerritsen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+M.++Goldstein">David M. Goldstein</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jens+Oliver++Funk">Jens Oliver Funk</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-416-7700. E-mail: <a href="/cdn-cgi/l/email-protection#7219171c5c1000131f171e163202001b1c111b021b13101b1d5c111d1f"><span class="__cf_email__" data-cfemail="a2c9c7cc8cc0d0c3cfc7cec6e2d2d0cbccc1cbd2cbc3c0cbcd8cc1cdcf">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00360&amp;href=/doi/10.1021%2Facs.jmedchem.7b00360" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6516–6527</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 30, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 March 2017</li><li><span class="item_label"><b>Published</b> online</span>25 July 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 August 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00360" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00360</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6516%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKen%2BA.%2BBrameld%252C%2BTimothy%2BD.%2BOwens%252C%2BErik%2BVerner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D15%26contentID%3Dacs.jmedchem.7b00360%26title%3DDiscovery%2Bof%2Bthe%2BIrreversible%2BCovalent%2BFGFR%2BInhibitor%2B8-%25283-%25284-Acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2B%2528PRN1371%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BSolid%2BTumors%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6527%26publicationDate%3DAugust%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00360"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">9418</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">48</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00360" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ken&quot;,&quot;last_name&quot;:&quot;A. Brameld&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;D. Owens&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;Verner&quot;},{&quot;first_name&quot;:&quot;Eleni&quot;,&quot;last_name&quot;:&quot;Venetsanakos&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Michael Bradshaw&quot;},{&quot;first_name&quot;:&quot;Vernon&quot;,&quot;last_name&quot;:&quot;T. Phan&quot;},{&quot;first_name&quot;:&quot;Danny&quot;,&quot;last_name&quot;:&quot;Tam&quot;},{&quot;first_name&quot;:&quot;Kwan&quot;,&quot;last_name&quot;:&quot;Leung&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Shu&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;LaStant&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Loughhead&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Ton&quot;},{&quot;first_name&quot;:&quot;Dane&quot;,&quot;last_name&quot;:&quot;E. Karr&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;E. Gerritsen&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;M. Goldstein&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Oliver Funk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;6516-6527&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00360&quot;},&quot;abstract&quot;:&quot;Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to develop an irreversible covalent inhibitor of FGFR1–4 for use in oncology indications. An irreversible covalent binding mechanism imparts many desirable pharmacological benefits including high potency, selectivity, and prolonged target inhibition. Herein we report the structure-based design, medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compound 34 (PRN1371), a highly selective and potent FGFR1–4 inhibitor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00360&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00360" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00360&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00360" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00360&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00360" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00360&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00360&amp;href=/doi/10.1021/acs.jmedchem.7b00360" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00360" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00360" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26pmid%3D28665128%26genre%3Darticle%26aulast%3DBrameld%26date%3D2017%26atitle%3DDiscovery%2Bof%2Bthe%2BIrreversible%2BCovalent%2BFGFR%2BInhibitor%2B8-%25283-%25284-Acryloylpiperazin-1-yl%2529propyl%2529-6-%25282%252C6-dichloro-3%252C5-dimethoxyphenyl%2529-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-one%2B%2528PRN1371%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BSolid%2BTumors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/jmcmar.2017.60.issue-15/20170810/jmcmar.2017.60.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0016.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to develop an irreversible covalent inhibitor of FGFR1–4 for use in oncology indications. An irreversible covalent binding mechanism imparts many desirable pharmacological benefits including high potency, selectivity, and prolonged target inhibition. Herein we report the structure-based design, medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compound <b>34</b> (PRN1371), a highly selective and potent FGFR1–4 inhibitor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Next generation sequencing of a broad array of solid tumors identified aberrant signaling of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4 in 7% of cancers, implicating the pathway in oncogenesis and as a potential point of therapeutic intervention.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> FGFR signaling is initiated by binding of an extracellular FGF ligand which leads to receptor dimerization and cross-phosphorylation of the tyrosine kinase domains. Upon activation, the phosphorylated kinase domains proceed to phosphorylate intracellular substrates such as PLCγ, Gab1, FRS2, and STAT1. Subsequent downstream signaling is complex and includes activation of the PI3K-Akt and the Ras/Raf/Mek/Erk pathways. In normal cells, FGFR signaling is important for diverse functions, some of which are cell differentiation, wound healing, and tissue homeostasis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A wide range of oncogenic alterations involving activation of the FGFR pathway have been identified including ligand or receptor amplification or overexpression, receptor mutations, and receptor translocations/fusion.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Small molecule FGFR tyrosine kinase inhibitors (TKIs) have shown clinical activity in the treatment of a variety of solid tumors such as metastatic urothelial,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> squamous cell lung,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> intrahepatic cholangiocarcinoma,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and breast cancers.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> First generation FGFR TKIs are not selective for the FGFR family, often inhibiting a broad range of additional kinases, commonly VEGFR1–3, PDGFR-α, and PDGFR-β. Several of these agents, such as dovitinib<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and lucitanib,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> are now in advanced clinical trials and have dose-limiting toxicities largely attributed to VEGFR inhibition. Next generation FGFR TKIs with improved selectivity are in early stage clinical trials (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), and promising clinical responses have been reported for <b>1</b> (AZD4547)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and <b>2</b> (infigratinib).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> While not entirely selective for FGFR1–3 and of moderate potency, <b>1</b> and <b>2</b> do not significantly inhibit VEGFR activity, thereby further validating FGFR inhibition alone as therapeutic modality. Single agent treatment with <b>2</b> provided objective response rates (ORR) of 22% and 36% in cholangiocarcinoma harboring FGFR2 translocations<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and in metastatic urothelial cancer harboring FGFR3 mutations or translocations,<a onclick="showRef(event, 'cit4a'); return false;" href="javascript:void(0);" class="ref cit4a">(4a)</a> respectively. Small molecule inhibitors that bind their target irreversibly through covalent bond formation are showing clinical benefits over their reversible comparators, particularly for oncology indications. First generation reversible inhibitors such as bortezomib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> targeting the proteasome, or erlotinib,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> an EGFR TKI, are being displaced by irreversible inhibitors carfilzomib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and afatinib,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> respectively, due to superior efficacy and relative safety profiles. An irreversible binding mechanism is especially well suited for TKIs that are required to compete with high intracellular ATP concentrations while maintaining selectively among the 500+ kinase family members.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Engaging a nonconserved cysteine residue for covalent binding within the small molecule binding site can impart substantial selectivity benefits over a reversible noncovalent inhibitor. The resulting sustained inhibition profile of an irreversible inhibitor requires new protein synthesis to restore pathway activation. Depending upon the rate of target protein turnover, it is possible to discover drugs that maintain a prolonged high level of target inhibition yet have rapid systemic clearance and a low body burden. Such a profile minimizes any reversible off-target mediated side effects and is ideal for use in combination therapies which are common in oncology.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Second-Generation Clinical FGFR Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We set out to discover highly selective irreversible inhibitors of FGFR1–4 as a targeted therapy for the treatment of solid tumors having FGFR alterations. The heterogeneity of FGFR isoforms and types of pathway alterations reported in a wide range of tumor types suggested that an inhibitor of all FGFR isoforms would provide the broadest therapeutic utility. For example, FGFR1/2 alterations are found in squamous non-small-cell lung cancer, FGFR2 alterations are found in gastric and cholangiocarcinoma, FGFR3 alterations are common in urothelial cancer, and FGFR4 alterations are found in hepatocellular carcinoma.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Targeting the kinase activity of these FGFR isoforms ensures pathway inhibition regardless of the mechanism of activation which may be due to ligand or receptor amplification or overexpression, receptor mutations, and receptor translocations/fusion. We sought compounds with high cellular potency capable of achieving complete target inhibition at low exposures followed by rapid systemic clearance. Herein we describe the design, structure–activity relationship (SAR), pharmacokinetics, and in vivo efficacy of a series of irreversible covalent FGFR1–4 inhibitors culminating in the selection of compound <b>34</b> (PRN1371) for advancement into clinical trials.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting with a focus on the design of compounds that covalently bind to cysteine residues, our lead generation strategy entailed identifying a suitable cysteine residue within the ATP binding pocket and applying structure-based design to generate small focused libraries of possible lead molecules. Within 8 Å of the ATP binding pocket of FGFR, there are three possible cysteine residues to target for covalent binding (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> One of these cysteine residues is only found in FGFR4 and was not pursued further due to the desire to discover an FGFR1–4 inhibitor. A second cysteine residue that would require a DFG-out ligand binding conformation is present in FGFR1–4; however it is also conserved in 16 additional kinases, presenting a possible selectivity challenge. On this basis, we focused upon covalent binding to Cys488 (FGFR1 residue numbering) which is conserved in only six additional kinases. Importantly, this cysteine is not present in any of the closely related off-targets, VEGFR2, PDGFRα, or PDGFRβ, for which high selectivity is desired.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural assessment of cysteine residues for covalent binding to FGFR1–4. (A) Several cysteine residues are proximal to the ATP binding pocket as illustrated by the spheres superimposed on the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a> X-ray structure. Listed for each highlighted cysteine sequence/structure location are the other kinases which share a cysteine at that position. (B) Structural alignment and overlay of three X-ray crystal structures (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQL">3GQL</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4F">3C4F</a>) of FGFR1 with different ligands occupying the ATP binding site. The highlighted cysteine residue (Cys488 in FGFR1) targeted for covalent binding by the compounds described in this work is located in the flexible glycine-rich loop and adopts a different conformation in each structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using multiple published X-ray crystal structures of reversible noncovalent small molecule ligands bound to FGFR1 (Protein Data Bank (PDB) codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQL">3GQL</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4F">3C4F</a>), it was apparent that Cys488 resides in a flexible region of the glycine-rich loop (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). Structure-based ligand design suggested the need to sample a range of linker lengths and trajectories spanning the region between the core molecular scaffold that recognizes the ATP binding pocket and the electrophile destined to covalently bond to Cys488. At the onset of the program, a number of diverse scaffolds were evaluated, and upon the basis of the available vectors toward Cys488, we quickly focused upon a series of 6-phenylpyridopyrimidines <b>3</b> and <b>4</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> first reported by researchers at Parke-Davis (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). SAR from this work established a preference for 2,6-dichloro or 3,5-dimethoxy substitutions at the 6-phenyl region to impart selectivity and potency. Inspection of the X-ray crystal structure of <b>4</b> bound to FGFR1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> revealed that the <i>t</i>-Bu-urea at the C-7 position could be used to approach the cysteine, but taking into consideration properties of druglikeness, we wanted to avoid a biarylurea functionality in the lead. In a subsequent publication from Parke-Davis, isosteric 6-phenylpyridopyrimidinones such as <b>5</b><a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> were reported to maintain FGFR activity. The N-8 position of the pyridopyrimidinone provided a good vector in the direction of Cys488 and was synthetically tractable for linker exploration. Furthermore, a covalent inhibitor of FGFR1–4 had recently been reported (<b>6</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>) for a dihydropyrimidopyrimidinone core scaffold.</div><figure id="cht2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Chemical Structures of Reported FGFR Inhibitors and Irreversible Covalent Inhibitor Design Hypothesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The design hypothesis used for initial lead generation is depicted in <a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>. Within a small series of compounds that differed in the region linking the pyridopyrimidinone scaffold to the electrophile (e.g., <b>7</b>–<b>10</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) a sharp SAR emerged. The <i>p</i>-phenethyl linker of compound <b>10</b> imparted reasonable potency of 38 nM against FGFR1 while maintaining a desirable >25-fold selectivity window over VEGFR2. Inhibition profiling at 1 μM <b>10</b> against a subset of kinases (FGR, c-Src, TNK1, and YES) with a conserved cysteine residue in the same location as Cys488 of FGFR1 identified none with >85% inhibition. In contrast, the original lead <b>5</b> was reported to be >10-fold more potent against c-Src than FGFR in a cellular assay.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> With this selectivity and potency profile, compound <b>10</b> was considered to be a viable lead and further optimization was initiated.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. FGFR1-4 and VEGFR2 Activity of Representative 8-Pyridopyrimidinone Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Biochemical potency against FGFR1–4 and selected off-target VEGFR2.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Estimated from single concentration inhibition of 66% at 1 μM.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Estimated from single concentration inhibition of 58% at 1 μM.</p></div></div><div></div></div><div class="NLM_p">Several assays were used to evaluate the SAR and guide lead optimization. In addition to traditional biochemical and cellular potency measurements, we relied extensively on an FGFR1 biochemical off-rate assay which has been described previously.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Briefly, preincubation of inhibitor with FGFR1 is followed by dilution and addition of a fluorescent competitive tracer. Time-dependent binding by the fluorescent tracer to FGFR1 is detected using time-resolved fluorescence resonance energy transfer (TR-FRET) and can only occur upon dissociation of the preincubated inhibitor. Our goal was to discover inhibitors that would rapidly and completely form an irreversible covalent bond upon binding to the receptor. Inhibitors with such a profile have durable and high target occupancy (e.g., >90%) at all time points of the experiment (15 min to 24 h). Tight binding inhibitors that do not form a covalent bond or only partially bond to a receptor have low target occupancy at all time points or a reduction in target occupancy over time. This assay does not replace a traditional kinetics analysis measuring <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> which defines the second order rate constant for covalent binding to a target protein.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While measurements of <i>k</i><sub>inact</sub> and <i>K</i><sub>i</sub> are of great utility, they are generally resource intensive, although a high throughput method was recently disclosed.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For the purposes of guiding our SAR optimization, the occupancy assay was adapted to a moderate throughput format and provided invaluable kinetics data.</div><div class="NLM_p">The cellular activity of compounds was routinely evaluated in two assays. Pathway inhibition in human umbilical vein endothelial cells (HUVEC) was determined by measuring bFGF induced ERK phosphorylation using Alphascreen technology.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Inhibition of cell proliferation was evaluated in the SNU16 gastric cancer cell line which overexpresses FGFR2.</div><div class="NLM_p">Two regions of the lead compound <b>10</b> were the focus of initial SAR studies. Modifications at the C-2 and N-8 positions were investigated while maintaining a 2-chloro-3,4-dimethoxy substitution pattern on the 6-phenyl substituent. <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> depicts the SAR observed when varying the linker between N-8 of the pyridopyrimidinone scaffold and the electrophilic acrylamide. The <i>m-</i>benzyl linker (<b>11</b>), which is reportedly optimal for the dihydropyrimidopyrimidinone scaffold (<b>6</b>), had only 65% FGFR1 occupancy at 15 min, indicative of incomplete covalent bond formation. Extending the linker by one carbon to yield the phenethyl analogs <b>12</b> and <b>16</b> improved the 15 min occupancy to 82% and 90%, respectively. Little difference in biochemical potency or occupancy was measured between the meta (<b>12</b>) and para (<b>16</b>) acrylamide regioisomers. However, the cellular potencies in both the HUVEC and SNU16 assays were 2- to 3-fold improved for the <i>p-</i>phenethyl linker (e.g., <b>16</b>, SNU16 IC<sub>50</sub> = 1.5 nM) when compared to the <i>m</i>-phenethyl analog (e.g., <b>12</b>, SNU16 IC<sub>50</sub> = 5.3 nM) perhaps indicative of a weak preference for the <i>p-</i>phenethyl linker. Introduction of nitrogen in the phenyl ring ortho or para to the acrylamide (e.g., <b>14</b>, <b>15</b>, <b>18</b>, <b>19</b>, and <b>20</b>) had a pronounced impact on the FGFR1 occupancy with sustained 100% occupancy observed at both the 15 min and 24 h time points for all the compounds. This improved FGFR1 occupancy occurred independent of the acrylamide regioisomer. Methylation of the acrylamide nitrogen reduced the biochemical potency and occupancy (e.g., <b>13</b> and <b>17</b>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. FGFR1 Biochemical Activity and Occupancy and Cellular Activity of Representative 8-Pyridopyrimidinone Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Biochemical potency against FGFR1.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">FGFR1 biochemical % target occupancy as determined by competition with fluorescent tracer following washout at 15 min or 24 h.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Inhibition of FGFb-mediated ERK phosphorylation in HUVEC primary cells.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Inhibition of proliferation of SNU16 gastric cancer cell line overexpressing FGFR2.</p></div></div><div></div></div><div class="NLM_p">In retrospect, it is apparent that the biochemical occupancy data for compounds <b>12</b>–<b>20</b> reflect a combination of the geometric preferences of the linker region and the intrinsic chemical reactivity of the acrylamide functional group. Reaction rate measurements between glutathione (GSH) and a diverse set of acrylamides have illuminated a broad spectrum of intrinsic reactivity that is particularly sensitive to substitutions proximal to the acrylamide. In the study reported by Flanagan et al., pyridoacrylamide, the electrophilic functional group in <b>14</b>, <b>15</b>, <b>18</b>, and <b>19</b>, is most reactive and had the shortest measured half-life of 0.13 h, whereas the <i>N</i>-methylacrylamide in <b>13</b> and <b>17</b> had a much longer half-life of 3.5 h.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We observed that the more reactive pyridoacrylamides suffered from poor whole blood stability (e.g., <b>18</b>, mouse whole blood <i>t</i><sub>1/2</sub> = 51 min) and made the decision to focus exclusively upon a <i>p-</i>phenethyl linker in subsequent SAR optimization (e.g., <b>16</b>).</div><div class="NLM_p">Next we sought to improve upon the poor aqueous solubility of compound <b>16</b> (<1 μg/mL in pH 7.4 PBS buffer). Building upon published SAR,<a onclick="showRef(event, 'ref19 ref26'); return false;" href="javascript:void(0);" class="ref ref19 ref26">(19, 26)</a> a series of alkylamino side chains were introduced at the C-2 amino position (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The more strongly basic amines (e.g., <b>21</b>, <b>22</b>, and <b>24</b>) showed a precipitous 3- to 20-fold loss in biochemical and cellular potencies. The less basic morpholine, methylpiperazine, and acylpiperazine (e.g., <b>23</b>, <b>25</b>, <b>27</b>, and <b>28</b>) retained low nanomolar biochemical potency and had improved FGFR1 occupancy at the 24 h time point (e.g., <b>23</b>, FGFR1 IC<sub>50</sub> = 1.4 nM, FGFR1 24 h occupancy of 97%). The introduction of the morpholine side chain did not substantially improve the aqueous solubility of compound <b>23</b> (<1 μg/mL). Despite the low aqueous solubility of <b>23</b>, results from a rat iv (2 mg/kg) and po (20 mg/kg) PK study showed encouraging exposure (AUC = 510 h·ng/mL) and oral bioavailability (<i>F</i> = 21%). Further characterization of compound <b>23</b> identified a potential hERG liability with 81% inhibition measured via a patch clamp assay at 1 μM concentration. Profiling of additional compounds in the hERG assay established that the alkylamino side chain was an essential feature of the hERG SAR. Removal of the alkylamino side chain (e.g., <b>16</b>, hERG % inh = 5%) or replacement with an alkylhydroxyl side chain (e.g., <b>29</b>, hERG % inh = 5%) largely eliminated hERG inhibition. Unfortunately, we were unable to identify a suitable side chain that maintained acceptable occupancy, cellular potency, oral bioavailability, and low hERG inhibition. While compound <b>29</b> addressed the hERG liability and maintained good cellular potency (e.g., <b>29</b>, HUVEC IC<sub>50</sub> = 2.4 nM, SNU16 IC<sub>50</sub> = 3.8 nM), it had no measurable exposure upon oral dosing in the mouse.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. FGFR1 Biochemical Activity, Cellular Activity, and hERG Potency of Representative 2-Amino Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Biochemical potency against FGFR1.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">FGFR1 biochemical % target occupancy as determined by competition with fluorescent tracer following washout at 15 min or 24 h.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Inhibition of FGFb-mediated ERK phosphorylation in HUVEC primary cells.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Inhibition of proliferation of SNU16 gastric cancer cell line overexpressing FGFR2.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">In vitro inhibition at 1 μM compound on the human ether-a-go-go-related gene (hERG) potassium channel current as measured using QPatch HT patch clamp system.</p></div></div><div></div></div><div class="NLM_p">Oral bioavailability reflects a complex interplay of metabolism and absorption, the latter of which is largely determined by permeability and solubility. Predicted intestinal permeability was consistently high across the series with a typical CACO-2 permeability rate of >5 × 10<sup>–6</sup> cm/s (A–B) and a low efflux ratio.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> From recognition of the importance of aqueous solubility, a renewed effort was made to identify more soluble linkers to span between N-8 of the pyridopyrimidinone scaffold and the electrophilic acrylamide. We sought to abandon aromatic features in this linker region and instead focus upon lower molecular weight aliphatic side chains that could accommodate alkoxy or amino moieties. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> depicts the SAR for a series of compounds with a 2,6-dichloro-3,4-dimethoxy substitution pattern on the 6-phenyl substituent and a simple aminomethyl at C-2. A diverse set of side chains that spanned a distance of 5–6 atoms between the 2-amino and acrylamide nitrogen atoms were discovered that maintained good occupancy and cellular potency. Comparing ethylpiperazine (e.g., <b>33</b>, FGFR1 occupancy 24 h of 50%, HUVEC IC<sub>50</sub> = 11 nM) to propylpiperazine (e.g., <b>34</b>, FGFR1 occupancy 24 h of 96%, HUVEC IC<sub>50</sub> = 1.5 nM) established a preference for the longer linker length. Reducing the ring size at the nitrogen of the acrylamide from piperdine (e.g., <b>37</b>, FGFR1 occupancy 24 h of 32%) to pyrrolidine (e.g., <b>38</b>, FGFR1 occupancy 24 h of 57%) to azetidine (e.g., <b>39</b>, FGFR1 occupancy 24 h of 110%) revealed a steep improvement in FGFR1 24 h occupancy. As hypothesized, the introduction of an aliphatic side chain succeeded in improving the aqueous solubility for all of these compounds. The greatest improvement was measured for the amine linkers (e.g., <b>34</b>, PBS solubility at pH 7.4 of 59 μM) and less so for the alkoxy linkers (e.g., <b>37</b>, PBS solubility at pH 7.4 of 3.3 μM). The change in side chain also addressed the potential for a hERG liability, with <b>36</b> and <b>39</b> both having <5% inhibition at 1 μM. This series of compounds represented a significant breakthrough for the project and warranted further ADME characterization to identify a clinical candidate.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. FGFR1 Biochemical Activity and Occupancy and Cellular Activity of Representative 8-Pyridopyrimidinone Derivatives Incorporating an Aliphatic Linker to the Electrophile</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0019.gif" alt="" id="GRAPHIC-d71e828-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Biochemical potency against FGFR1.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">FGFR1 biochemical % target occupancy as determined by competition with fluorescent tracer following washout at 15 min or 24 h.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Inhibition of FGFb-mediated ERK phosphorylation in HUVEC primary cells.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Inhibition of proliferation of SNU16 gastric cancer cell line overexpressing FGFR2.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Kinetic aqueous solubility (pH 7.4).</p></div></div><div></div></div><div class="NLM_p">A widely appreciated potential liability of Michael acceptors, such as acrylamides, is the possibility for undesirable reactions with off-target thiols, such as abundant cysteine-containing proteins or GSH.<a onclick="showRef(event, 'ref23 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref28">(23, 28)</a> These off-target reactions may translate to rapid clearance and poor ADME properties. We previously have described a reactivity assay used to characterize reversible covalent inhibitors of BTK.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The assay measures the <i>K</i><sub>d</sub> between inhibitor and a simple thiol, β-mercaptoethanol (BME), by LC–MS monitoring of the loss of inhibitor and formation of inhibitor + BME adduct. In the absence of a chemical equilibrium, as is the case for irreversible inhibitors, we adapted the assay to measure <i>K</i><sub>d</sub> apparent at a fixed incubation time of 2 h. The measured BME <i>K</i><sub>d</sub> apparent for compounds <b>37</b>–<b>39</b> spans 3 log units from 43 to 4140 μM (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Reducing the ring size at the nitrogen of the acrylamide systematically increases the chemical reactivity. A similar trend is observed between the aminopiperidine (e.g., <b>35</b>, BME <i>K</i><sub>d</sub> = 933 μM) and aminoazetidine (e.g., <b>36</b>, BME <i>K</i><sub>d</sub> = 43 μM) compounds.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Comparison between Electrophile Reactivity toward β-Mercaptoethanol and Selected ADME Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Chemical reactivity assay measuring apparent <i>K</i><sub>d</sub> of compounds toward β-mercaptoethanol (BME) after 2 h incubation.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Percent compound remaining after 2 h incubation with human plasma or human whole blood.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Metabolic stability in pooled human liver S9 fraction with (w/) and without (w/o) NADPH cofactor.</p></div></div><div></div></div><div class="NLM_p"><a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> compares the measured BME apparent <i>K</i><sub>d</sub> values to several in vitro ADME properties. There is an inverse trend between BME reactivity and plasma stability. A subset of compounds with the highest FGFR1 24 h occupancy from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were found to be most reactive toward BME and have the greatest plasma instability (e.g., <b>36</b>, BME <i>K</i><sub>d</sub> = 43 μM, 2 h plasma = 67% remaining and <b>39</b>, BME <i>K</i><sub>d</sub> = 43 μM, 2 h plasma = 32% remaining). On this basis, it became clear that the improved FGFR1 24 h occupancy of the azetidine acrylamide compounds <b>36</b> and <b>39</b> is a likely consequence of heightened chemical reactivity. Human liver S9 stability, with or without cofactor NADPH, appears to be independent of BME reactivity. This result was surprising to us as we anticipated the electrophile to be a metabolic soft-spot for oxidation, and this may have been correlated with chemical reactivity. As a consequence, when profiling the in vitro clearance properties of irreversible inhibitors, we found it beneficial to include models of both hepatic and extra-hepatic clearance mechanisms, as others also have reported.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Rat iv (2 mg/kg) and po (20 mg/kg) PK for compound <b>36</b> demonstrated low oral exposure (AUC = 310 h·ng/mL) and poor oral bioavailability (<i>F</i> = 12%), consistent with the in vitro predictions.</div><div class="NLM_p">Compound <b>34</b> presents a unique profile of high biochemical and cellular potency (FGFR1 IC<sub>50</sub> = 0.6 nM, SNU16 IC<sub>50</sub> = 2.6 nM), prolonged target engagement (FGFR1 occupancy 24 h = 96%), < 30% hERG inhibition at 1 μM, and good predicted ADME stability with BME reactivity <i>K</i><sub>d</sub> > 100 μM. A rat iv (2 mg/kg) PK study of compound <b>34</b> showed rapid clearance (Cl = 160 mL min<sup>–1</sup> kg<sup>–1</sup>), yet dosing po (20 mg/kg) demonstrated high oral exposure (AUC = 4348 h·ng/mL) and a reasonable half-life (<i>t</i><sub>1/2</sub> = 3.8 h). Broader kinome-wide biochemical profiling of <b>34</b> against 251 kinases identified only FGFR1–4 and CSF1R as being potently inhibited (e.g., IC<sub>50</sub> < 20 nM) (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf" class="ext-link">Supporting Information Table S1</a>). The ATP binding site of CSF1R does not have a proximal cysteine residue, and compound <b>34</b> binds noncovalently, as determined by recovery of kinase activity upon dialysis. Consistent with reversible binding, there is a large shift between the biochemical potency (8.1 nM IC<sub>50</sub>) and the cellular potency of CSF1R inhibition (>1500 nM IC<sub>50</sub>), rendering it physiologically irrelevant.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Selectivity Profile of Compound <b>34</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> ± Std Dev (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">kinase<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> ± Std Dev (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.1 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">FLT-4</td><td class="colsep0 rowsep0" align="left">410 ± 9 (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.2 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">556 ± 6 (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="left">4.1 ± 0.7 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">LYNB</td><td class="colsep0 rowsep0" align="left">631 ± 1 (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4</td><td class="colsep0 rowsep0" align="left">19.3 ± 4.7 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">LYNA</td><td class="colsep0 rowsep0" align="left">639 ± 5 (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF1R</td><td class="colsep0 rowsep0" align="left">8.1 ± 0.6 (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="left">705 ± 63 (<i>n</i> = 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX</td><td class="colsep0 rowsep0" align="left">272 ± 7 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">PERK</td><td class="colsep0 rowsep0" align="left">792 ± 50 (<i>n</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="left">371 ± 12 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">TAOK2</td><td class="colsep0 rowsep0" align="left">1175 ± 43 (<i>n</i> = 2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Potency of biochemical inhibition by compound <b>34</b> of kinases that demonstrated >50% inhibition at 1 μM from a panel of 251 different kinases (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf" class="ext-link">Supporting Information</a> for inhibition data for full kinase panel).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values for kinase inhibition as determined using the Caliper electrophoresis method. Uncertainties are the standard deviation (Std Dev) for multiple independent determinations (<i>n</i>).</p></div></div></div><div class="NLM_p">The preparation of compound <b>34</b>, described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, begins with chlorination of 3,5-dimethoxytoluene <b>42</b>, followed by benzylic bromination with NBS and displacement with sodium cyanide to afford compound <b>43</b> in three steps. Condensation with aldehyde <b>44</b> occurs under basic conditions in DMF to afford imine <b>45</b>, which is readily hydrolyzed to produce key intermediate <b>46</b>. The linker is introduced selectively at the N-8 position with iodide <b>41</b>, which itself is prepared in two steps from compound <b>40</b>. The resulting thioether <b>47</b> is activated at the 2-position of the pyrimidine system by oxidization with <i>m</i>-CPBA to afford the corresponding sulfone, which is then readily displaced with methylamine<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> to furnish the penultimate intermediate <b>48</b>. Boc deprotection is followed by acylation of the piperazine nitrogen with acryloyl chloride to yield compound <b>34</b> in 41% yield after chromatography.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of Compound <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In selecting a clinical candidate, we sought to identify a compound with a pharmacological profile of complete and rapid target inhibition with minimal exposure and low body burden. The high cellular potency of compound <b>34</b> encouraged us to further characterize its binding kinetics and pharmacokinetics. To achieve rapid and durable target inhibition requires a fast on-rate and slow or nonexistent off-rate. By measurement of the progress curves of peptide substrate phosphorylation at different compound concentrations, the initial velocity (<i>V</i><sub>i</sub>), steady state velocity (<i>V</i><sub>s</sub>), and observed constant of inhibition (<i>K</i><sub>obs</sub>) for compound <b>34</b> were determined. The hyperbolic shape of the progress curves indicated time-dependent inhibition which is a hallmark of irreversible inhibitors and enabled the calculation of <i>k</i><sub>inact</sub>, <i>K</i><sub>i</sub>, and <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> values for binding to FGFR1–4 (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Highly efficient covalent target engagement is apparent for FGFR1–3 with a calculated <i>K</i><sub>i</sub> of 1.3–2.2 nM and <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> ratio of 0.46–1.2 (μM<sup>–1</sup> s<sup>–1</sup>). While the observed weaker affinity for FGFR4 (e.g., <i>K</i><sub>i</sub> = 73 nM) is consistent with the biochemical and cellular IC<sub>50</sub> data, the kinetics studies also confirm covalent irreversible binding to FGFR4.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Kinetics Values of Compound <b>34</b> Binding to FGFR1-4</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub> (s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> (μM<sup>–1</sup> s<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="left">0.0019 ± 0.0015</td><td class="colsep0 rowsep0" align="left">1.6 ± 1.1</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="left">0.00092 ± 0.00016</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="left">0.00097 ± 0.00015</td><td class="colsep0 rowsep0" align="left">2.2 ± 0.5</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4</td><td class="colsep0 rowsep0" align="left">0.00066 ± 0.00007</td><td class="colsep0 rowsep0" align="left">73 ± 22</td><td class="colsep0 rowsep0" align="left">0.010 ± 0.003</td></tr></tbody></table></div></div><div class="NLM_p">To minimize off-target pharmacology and maximize tolerability when used in combination therapy, the ideal PK profile of a slow off-rate inhibitor consists of high oral absorption followed by rapid systemic clearance. PK studies of compound <b>34</b> in rat, dog, and cynomolgus monkey showed rapid iv clearance in all species; however there were large species differences in oral exposure and bioavailability for monkey compared to rat and dog (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). In rat, high exposure upon oral dosing (e.g., <i>C</i><sub>max</sub> = 1785 ng/mL, AUC = 4348 ng·h/mL) and >100% bioavailability (<i>F</i>) suggested good absorption and partial saturation of clearance mechanisms at the 20 mg/kg dose. Unique to the rat, there is a large difference in half-life between the iv (<i>t</i><sub>1/2</sub> = 0.8 h) and po (<i>t</i><sub>1/2</sub> = 3.8 h) routes of administration, also indicative of possible saturation of a clearance mechanism upon oral dosing. In the dog, the same methylcellulose suspension formulation used for the rat gave low oral absorption and bioavailability (<i>F</i> < 15%). We hypothesized that the less acidic gastric and intestinal pH of the dog may be contributing to low absorption of the free base of compound <b>34</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Coadministration of a molar equivalent of citric acid improved the oral absorption of a 10 mg/kg dose (e.g., <i>C</i><sub>max</sub> = 1103 ng/mL, AUC = 1134 ng·h/mL, <i>F</i> = 94%) and brought it in line with the rat PK. Exceptionally low oral exposure in the monkey (e.g., <i>C</i><sub>max</sub> = 96 ng/mL, AUC = 84 ng·h/mL) was initially a cause for concern. We were able to attribute this to intestinal Cyp3A4 mediated metabolism. It has been reported that the bioavailability in monkey of compounds that undergo intestinal metabolism is much lower than that of rat or human.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For neratinb and ibrutinib, two covalent kinase inhibitors with acrylamide Michael acceptors that undergo extensive Cyp3A4 mediated metabolism, monkey PK grossly overestimates clearance and underestimates absorption, making monkey an inappropriate species for the prediction of human absorption.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> On this basis, we were comfortable with the preclinical PK of compound <b>34</b> as it predicted our desired profile of high oral absorption followed by rapid clearance.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters of Compound <b>34</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">rat<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">dog<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">monkey<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">160</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">42.9</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">7.20</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2.90</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">1.14</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.764</td><td class="colsep0 rowsep0" align="left">3.77</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">0.58</td><td class="colsep0 rowsep0" align="left">0.349</td><td class="colsep0 rowsep0" align="left">0.486</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">596</td><td class="colsep0 rowsep0" align="left">1785</td><td class="colsep0 rowsep0" align="left">1087</td><td class="colsep0 rowsep0" align="left">1103</td><td class="colsep0 rowsep0" align="left">999</td><td class="colsep0 rowsep0" align="left">95.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">208</td><td class="colsep0 rowsep0" align="left">4348</td><td class="colsep0 rowsep0" align="left">284</td><td class="colsep0 rowsep0" align="left">1344</td><td class="colsep0 rowsep0" align="left">472</td><td class="colsep0 rowsep0" align="left">84.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">208</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Female Sprague-Dawley rats dosed at 2 mg/kg iv and 20 mg/kg po.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Male beagle dogs dosed at 2 mg/kg iv and 10 mg/kg po.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Male cynomolgus monkeys dosed at 1.23 mg/kg iv and 10 mg/kg po.</p></div></div></div><div class="NLM_p">Several in vivo studies of compound <b>34</b> were conducted to understand the relationship between PK and FGFR pathway inhibition. Exploratory mouse studies identified the chemokine CCL2 as elevated following tail vein injection of bFGF. Specifically, upon stimulation with 10 μg of bFGF, it was found that CCL2 increased from a basal level of 301 ± 101 pg/mL to a level of 1487 ± 537 pg/mL at 4 h poststimulation. We evaluated the percent inhibition of bFGF-induced CCL2 at 1, 5, and 12 h after oral administration of a 10 mg/kg dose of compound <b>34</b> in rats. The levels of compound <b>34</b> in circulation were measured at the same time points to assess whether CCL2 inhibition was driven by long-lasting binding of compound <b>34</b> to FGFR or by compound in circulation. The plasma concentration of compound <b>34</b> peaked at 538 ± 88 ng/mL 1 h after dosing and fell to a nearly undetectable level after 12 h (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b). Strong inhibition of CCL2 was sustained from 99.5% ± 3.8% at 1 h to 93.5% ± 4.7% 12 h after dosing, suggesting long-lasting FGFR target inhibition by compound <b>34</b>. The effect of noncovalent FGFR inhibitor <b>2</b> on CCL2 inhibition was also investigated. In contrast to compound <b>34</b>, the level of CCL2 inhibition significantly declined from 98.2% ± 4.1% at 5 h to 59.5% ± 11.6% at 12 h for compound <b>2</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A), indicating that the covalent binding mechanism of compound <b>34</b> to FGFR is likely responsible for the long lasting inhibition of CCL2.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rat in vivo inhibition of bFGF-induced CCL2 production (black line, right <i>y</i>-axis) by a 10 mg/kg dose of compound <b>2</b> or <b>34</b> and associated compound plasma levels (gray line, left <i>y</i>-axis) at 1, 5, and 12 h postdose (<i>n</i> = 5 per group): (A) reversible compound <b>2</b>; (B) irreversible covalent compound <b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>34</b> was evaluated in pharmacodynamics and efficacy studies using a SNU16 gastric cancer xenograft mouse model with high overexpression of FGFR2. In nude mice implanted with subcutaneous SNU16 tumors, pFGFR2 levels in the tumor were measured via Western blotting at 8 h following a 10 mg/kg oral dose (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). Low levels of pFGFR2 confirmed the ability of compound <b>34</b> to block FGFR2 activity in tumor tissue. Efficacy was determined by measuring tumor growth inhibition in the same SNU16 xenograft model (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). Compound <b>34</b> induced a dose-dependent reduction in tumor volume and up to 68% tumor growth inhibition at the highest dose of 10 mg/kg b.i.d. following 27 days of treatment. All doses were well tolerated with no significant body weight loss.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK/PD and efficacy of compound <b>34</b> in a SNU16 mouse xenograft model. (A) Western blots showing blockade of pFGFR within the tumor 8 h postdose. Lanes 1–4 are individual mice dosed with vehicle, and lanes 5–8 are individual mice dosed with compound <b>34</b> at 10 mg/kg q.d. (B) Tumor growth inhibition (TGI) dose response upon oral administration of compound <b>34</b> (<i>n</i> = 10 per dose group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With good in vivo efficacy and PK, compound <b>34</b> was progressed into preclinical safety evaluations including 28 day GLP toxicology studies in rats and dogs. The toxicological findings were consistent with those reported for other FGFR inhibitors, predominantly phosphorus dysregulation and concomitant soft tissue mineralization.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Phosphorus homeostasis is dependent upon FGF23 signaling in the kidney. As a consequence, clinical on-target mediated effects of FGFR blockade include elevated serum FGF23, phosphate, and vitamin D.<a onclick="showRef(event, 'cit4b ref34'); return false;" href="javascript:void(0);" class="ref cit4b ref34">(4b, 34)</a> The combination of a clean preclinical safety profile, favorable human PK projections, and efficacy in the xenograft models gave us confidence to advance compound <b>34</b> into human clinical trials.</div><div class="NLM_p">A phase 1 dose escalation study is being conducted in patients with advanced solid tumors and metastatic disease to assess pharmacokinetics, tolerability, and objective response rate, among other end points (ClinicalTrials.gov identifier NCT02608125). Compound <b>34</b> free base has been administered orally once daily as powder in a capsule on a 28-day continuous schedule. Human plasma concentrations for doses ranging from 15 to 35 mg (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A) confirm good oral exposure, rapid systemic clearance, no accumulation from day 1 to day 15, and a dose-dependent increase in AUC.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Serum phosphate, a pharmacodynamic marker of FGFR inhibition, is increased for all doses studied and shows a dose-dependent increase between 20 and 35 mg, despite the administration of prophylactic phosphate binders (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). Additional cohorts and dosing regimens are being explored in ongoing clinical studies and will be reported in due course.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Phase I clinical data for once daily oral administration of compound <b>34</b>. (A) Total plasma concentration over time. (B) Percent change at day 8 of serum phosphate, a pharmacodynamic marker of FGFR inhibition; the asterisk (∗) indicates prophylactic administration of phosphate binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Structure-based design and medicinal chemistry optimization that was focused on maximizing FGFR target occupancy led to the discovery of compound <b>34</b>, an irreversible nanomolar inhibitor of FGFR1–4. Several specific assays were critical in guiding the lead optimization process including measures of FGFR1 occupancy, human plasma stability, and Michael acceptor chemical reactivity. Initial progress toward optimization of a potent lead molecule (compound <b>10</b>) having a <i>p-</i>phenethyl linker between N-8 of the pyridopyrimidinone scaffold and the electrophilic acrylamide was unsuccessful in identifying a clinical candidate primarily due to poor solubility and a potential hERG liability. Subsequent incorporation of an aliphatic amine in place of the <i>p-</i>phenethyl linker led to compound <b>34</b> which maintained high FGFR1 occupancy with improved solubility and exceptional oral bioavailability. A low dose, high clearance, irreversible covalent drug has the potential for a large therapeutic window due to durable target inhibition that continues after the drug has cleared systemic circulation. Compound <b>34</b> has this ideal PK profile and, as a consequence of its irreversible binding mechanism, demonstrates extended FGFR inhibition in vivo after plasma concentrations are below the limits of quantitation. For irreversible inhibitors, the rate of new protein synthesis largely determines the duration of target inhibition. The protein half-life of FGFR3 has been reported to be approximately 4 h and is context dependent.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> PK/PD studies in preclinical xenograft models confirmed blockade of FGFR signaling and potent tumor growth inhibition. Initial cohorts of a phase 1 dose escalation trial support the predicted PK profile, were well tolerated, and warrant further clinical investigation. Expanded trials in a targeted patient population will be required to demonstrate the clinical benefits of an irreversible covalent binding mechanism for FGFR inhibition.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cell Lines and Reagents</h3><div class="NLM_p last">The gastric cancer cell line SNU16 was purchased from American Tissue Culture Collection (ATCC, Manassas, VA) and cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS, Gibco catalog no. 26140-079). HUVECs (Genlantis catalog no. PH20005N) were maintained in endothelial cell growth medium (Genlantis catalog no. PM211500) containing 10% FBS. Cells were maintained in standard culture conditions of 37 °C, 5% CO<sub>2</sub>, and 95% humidity and were kept in culture for up to 15–20 passages.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>K</i><sub>d</sub> Determination Using β-Mercaptoethanol</h3><div class="NLM_p last">Solutions were prepared containing 0, 1.5, 15, 150, and 1500 mM β-mercaptoethanol (BME) in a 1:1 mixture of ethanol and phosphate buffered saline (pH 7.4, PBS). Aliquots of a 10 mM DMSO stock solution of test compound (10 μL) were separately added to 90 μL aliquots of the above-described ethanol/PBS solutions containing 0–1500 mM BME. After these solutions had been allowed to stand at room temperature for 2 h, they were analyzed using an Agilent 1200 LCMS system equipped with a 50 mm × 2 mm Phenomenex Luna 5 μm C18 100A column. Samples were eluted using a gradient of acetonitrile and water, with both solvents containing 0.1% formic acid. Peaks corresponding to parent and BME adduct were identified by their masses, and the percent parent in each sample was determined by measuring the area under the curve for the extracted mass peaks from the positive ion trace corresponding to parent and BME adduct. Percent parent was plotted versus the log of the BME concentration using GraphPad Prism to determine an apparent <i>K</i><sub>d</sub> for the reaction.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Kinase Assays</h3><div class="NLM_p last">Enzyme inhibition was determined using a Caliper capillary electrophoresis system that separates phosphorylated and nonphosphorylated peptides on the basis of charge. Different concentrations of inhibitor were first preincubated with enzyme for 15 min. The reaction was initiated with addition of peptide substrate, ATP, and Mg<sup>2+</sup> and incubated at 25 °C for 3 h. To stop the reaction, the mixture was quenched with EDTA. The buffer was 100 mM HEPES, pH 7.5, 0.1% BSA, 0.01% Triton X-100, 1 mM DTT, 10 mM MgCl<sub>2</sub>, 10 mM sodium orthovanadate, 10 μM β-glycerophosphate, and 1% DMSO. The ATP concentration of the reaction was at the predetermined value of the <i>K</i><sub>m</sub> for ATP. All enzyme inhibition data were acquired by Nanosyn, Inc. (Santa Clara, CA; <a href="http://www.nanosyn.com" class="extLink">www.nanosyn.com</a>). Kinase selectivity was also evaluated using the Nanosyn 250 kinase panel.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> ERK Phosphorylation in HUVECs</h3><div class="NLM_p last">Human umbilical vein endothelial cells (HUVECs) were incubated in media supplemented with 10% FBS and seeded at 30 000 cells per well in a 96-well plate overnight. HUVECs were then transferred into serum free media 1 h before compound treatment. A compound concentration series was added to cells and incubated for 1 h at 37 °C. Cells were then stimulated with either 50 ng/mL of FGF2 (R&D Systems catalog no. 233-FG-025) or 50 ng/mL of VEGF (R&D Systems catalog no. 293-VE-050) for 10 min. Ice cold PBS was added to stop the reaction, and cells were washed three times to remove media. A pERK SureFire kit (PerkinElmer) was utilized to determine ERK phosphorylation using an Envision multilabel plate reader (PerkinElmer).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> FGFR1 Residence Time Using Fluorescence Competition</h3><div class="NLM_p last">Using an assay buffer of 50 mM Hepes pH 7.5, 10 mM MgCl<sub>2</sub>, 0.01% Triton-X 100, and 1 mM EGTA, 1 μL of 15 μM compound was added to 9 μL of 0.5 μM FGFR1 (Invitrogen PV4105) in a 96-well polypropylene plate. Following 60 min of incubation, the mixture was diluted in assay buffer 100-fold. An amount of 10 μL of diluted mixture was transferred to a Greiner 384-well black plate. Europium-coupled Anti-6XHis Ab (PerkinElmer AD0205) and Cy5-labeled pyridopyrimidinone tracer were added to a final concentration of 15 nM and 0.75 μM, respectively, in 20 μL volume. Data were acquired using a PerkinElmer Envision plate reader (model 2101) containing LANCE TR-FRET compatible excitation and emission filters. Fluorescence at 665 nM and 615 nM wavelengths was collected at various times. In each experiment, a condition that provides the maximum signal (max) was acquired consisting of the signal from enzyme, europium-coupled Anti-6XHis Ab, and tracer in the absence of test compound. A background signal (bkg) was also acquired where a 1 μM concentration of PP-ir was added to completely block tracer binding. Data for each test compound were reported as % occupancy, which is calculated as 100 × (1 – (compd – bkg)/(max – bkg)).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> FGFR1 Progress Curve Analysis</h3><div class="NLM_p last">Progress curves of FGFR1 peptide (5-FAM-KKKKEEIYFFF-NH2) phosphorylation were acquired at six concentrations. The real-time curves were obtained for a total of 5 h using the climate controlled Caliper LabChip instrument. The obtained curves were fit using XLfit4 software to the time dependent inhibition equation: [P] = <i>V</i><sub>s</sub><i>t</i> + ((<i>V</i><sub>i</sub> – <i>V</i><sub>s</sub>)/<i>K</i><sub>obs</sub>)(1 – exp(−<i>K</i><sub>obs</sub><i>t</i>)). In the equation, <i>V</i><sub>i</sub> is the initial velocity, <i>V</i><sub>s</sub> is the steady state velocity, and <i>K</i><sub>obs</sub> reflects the rate of inactivation. For time dependent inhibitors, the obtained <i>K</i><sub>obs</sub> values were plotted against compound concentration using either a hyperbolic or a linear fit. From these plots, <i>k</i><sub>inact</sub> and <i>K</i><sub>i</sub> were determined. Progress curve data were acquired by Nanosyn, Inc. (Santa Clara, CA; <a href="http://www.nanosyn.com" class="extLink">www.nanosyn.com</a>).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> SNU16 Cell Proliferation</h3><div class="NLM_p last">SNU16 cells were first seeded into 384-well plates and compounds added such that the highest final compound concentration is 5 μM. Cells were incubated with compound for 72 h at 37 °C. To detect viability, the Presto-Blue cell viability reagent (Life Technologies catalog no. A13261) was added per manufacturer’s instructions. Plates were read using an Analyst HT with a fluorescent mode employing 530 nm excitation and 590 nm emission.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Xenograft Mouse Studies</h3><div class="NLM_p last">For xenograft studies with SNU16 cells, a suspension of 1 × 10<sup>7</sup> cells were injected at the upper right back of 7 week old female nude mice (Crown Bioscience, Taichang, P. R. China). The care and treatment of experimental animals were in accordance with institutional guidelines. Mice were randomized (<i>n</i> = 10 per group) once the mean tumor volume had reached an average tumor size of ∼150–180 mm<sup>3</sup>, and there were no exclusion criteria. Compound <b>34</b> was suspended in 0.5% methylcellulose w/w in deionized water. Tumor volumes were measured three times weekly using a caliper, and the volume was expressed in mm<sup>3</sup> using the formula <i>V</i> = 0.5<i>a</i><i>b</i><sup>2</sup> where <i>a</i> and <i>b</i> are the long and short diameters of the tumor, respectively. Tumor weight was measured at study termination. SNU16 tumor cell lysates were evaluated for pFGFR by SDS–PAGE and immunoblotting using a rabbit anti-pFGFR2 antibody (Cellular Signaling Technology catalog no. 3471S) and a mouse anti-FGFR2 antibody (R&D Systems catalog no. MAB6841).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Synthetic Methods</h3><div class="NLM_p last">Synthetic methods for compounds <b>7</b>–<b>31</b> and <b>32</b>–<b>39</b> are described in patent applications WO2014182829<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and WO2015120049,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> respectively. Unless otherwise noted, all materials were obtained from commercial suppliers and used as obtained. Anhydrous organic solvents were purchased from Aldrich packaged under N<sub>2</sub> in Sure/Seal bottles and used directly. <sup>1</sup>H NMR spectra were recorded on a Bruker AV-400 (400 MHz) spectrometer at ambient temperature. Chemical shifts are reported in parts per million (δ) and are calibrated using residual undeuterated solvent as an internal reference. Data for <sup>1</sup>H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, or combinations thereof. Purity was assayed by HPLC (XBRIDGE C18 column, 3.5 μm × 50 mm) with a gradient of 10–100% acetonitrile (containing 0.05% TFA) in 0.05% aqueous TFA with UV detection at λ= 210 and 254 nm. All final compounds were obtained with ≥95% purity.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one, <b>34</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 8.62 (s, 1H), 7.88 (d, <i>J</i> = 4.5 Hz, 1H), 7.68 (s, 1H), 6.98 (S, 1H), 6.77 (dd, <i>J</i> = 10.5, 16.7 Hz, 1H), 6.08 (dd, <i>J</i> = 2.4, 16.7 Hz), 5.65 (dd, <i>J</i> = 2.4, 10.5 Hz, 1H), 4.41–4.25 (m, 2H), 3.96 (s, 6H), 3.49–3.43 (m, 4H), 2.92 (d, <i>J</i> = 4.9 Hz, 3H), 2.42- 2.25 (m, 6H), 1.90–1.78 (m, 2H). MS (ESI, pos ion) <i>m</i>/<i>z</i>: 561.1 (M+ 1). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) 165.3, 162.2, 161.1, 158.8, 155.8, 154.6, 136.3, 136.0, 127.7, 127.5, 125.0, 115.3, 97.5, 56.6, 56.0, 55.9, 53.3, 52.7, 45.8, 41.9, 39.6, 39.5, 28.5, 24.9.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00360">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00360" class="ext-link">10.1021/acs.jmedchem.7b00360</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Table S1 showing biochemical kinase inhibition profiling of compound <b>34</b> against 251 kinases (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings with FGFR1 enzyme and cellular inhibition data for compounds <b>7</b>–<b>39</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf">jm7b00360_si_001.pdf (112.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_002.csv">jm7b00360_si_002.csv (3.01 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00360" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken A. Brameld</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8643-3218" title="Orcid link">http://orcid.org/0000-0001-8643-3218</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4229272c6c2030232f272e260232302b2c212b322b23202b2d6c212d2f"><span class="__cf_email__" data-cfemail="f398969ddd9181929e969f97b383819a9d909a839a92919a9cdd909c9e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy D. Owens</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik Verner</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eleni Venetsanakos</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Michael Bradshaw</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vernon T. Phan</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danny Tam</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwan Leung</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Shu</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob LaStant</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Loughhead</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Ton</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dane E. Karr</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary E. Gerritsen</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David M. Goldstein</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Oliver Funk</span> - <span class="hlFld-Affiliation affiliation">Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i34" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i34"> Abbreviations Used</h2><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">% bioavailability</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma–concentration time curve</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">two times a day</p></td></tr><tr><td class="NLM_term">BQL</td><td class="NLM_def"><p class="first last">below quantitation limit</p></td></tr><tr><td class="NLM_term">BME</td><td class="NLM_def"><p class="first last">β-mercaptoethanol</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>0</sub></td><td class="NLM_def"><p class="first last">concentration extrapolated to time zero following iv administration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">total body clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal plasma concentration</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde 3-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cell</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitory concentration 50% (concentration causing half-maximal inhibition)</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous administration</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor, also known as VEGFR2</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>inact</sub></td><td class="NLM_def"><p class="first last">maximal inactivation</p></td></tr><tr><td class="NLM_term">LYN</td><td class="NLM_def"><p class="first last">Lck-Yes-related novel protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">objective response rate</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">elimination half-life</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to maximum concentration</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Helsten, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomson, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1078-0432.CCR-14-3212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26373574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=259-267&issue=1&author=T.+Helstenauthor=S.+Elkinauthor=E.+Arthurauthor=B.+N.+Tomsonauthor=J.+Carterauthor=R.+Kurzrock&title=The+FGFR+Landscape+in+Cancer%3A+Analysis+of+4%2C853+Tumors+by+Next-Generation+Sequencing&doi=10.1158%2F1078-0432.CCR-14-3212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span></div><div class="casAuthors">Helsten, Teresa; Elkin, Sheryl; Arthur, Elisa; Tomson, Brett N.; Carter, Jennifer; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-267</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mol. profiling may have prognostic and predictive value, and is increasingly used in the clin. setting.  There are more than a dozen fibroblast growth factor receptor (FGFR) inhibitors in development.  Optimal therapeutic application of FGFR inhibitors requires knowledge of the rates and types of FGFR aberrations in a variety of cancer types.  Exptl. Design: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clin. Lab.  Improvement Amendments (CLIA) lab. (Foundation Medicine) using next-generation sequencing (182 or 236 genes), and analyzed by N-of-One.  Results: FGFR aberrations were found in 7.1% of cancers, with the majority being gene amplification (66% of the aberrations), followed by mutations (26%) and rearrangements (8%).  FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%.  Almost every type of malignancy examd. showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant); breast (18%); endometrial (∼13%), squamous lung cancers (∼13%), and ovarian cancer (∼9%).  Among 35 unique FGFR mutations seen in this dataset, all but two are found in COSMIC.  Seventeen of the 35 are known to be activating, and 11 are transforming.  Conclusions: FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations.  These data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.  Clin Cancer Res; 22(1); 259-67. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_eQBJarU4mLVg90H21EOLACvtfcHk0lgeNLlyyotysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D&md5=7172cbee01331fe0d3fac5dada295fc2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3212%26sid%3Dliteratum%253Aachs%26aulast%3DHelsten%26aufirst%3DT.%26aulast%3DElkin%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DB.%2BN.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DThe%2520FGFR%2520Landscape%2520in%2520Cancer%253A%2520Analysis%2520of%25204%252C853%2520Tumors%2520by%2520Next-Generation%2520Sequencing%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D1%26spage%3D259%26epage%3D267%26doi%3D10.1158%2F1078-0432.CCR-14-3212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Belov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">a015958</span><span class="refDoi"> DOI: 10.1101/cshperspect.a015958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1101%2Fcshperspect.a015958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslejtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=a015958&issue=6&author=A.+A.+Belovauthor=M.+Mohammadi&title=Molecular+mechanisms+of+fibroblast+growth+factor+signaling+in+physiology+and+pathology&doi=10.1101%2Fcshperspect.a015958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology</span></div><div class="casAuthors">Belov, Artur A.; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">A015958/1-A015958/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPEU</span>;
        ISSN:<span class="NLM_cas:issn">1943-0264</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) signal in a paracrine or endocrine fashion to mediate a myriad of biol. activities, ranging from issuing developmental cues, maintaining tissue homeostasis, and regulating metabolic processes.  FGFs carry out their diverse functions by binding and dimerizing FGF receptors (FGFRs) in a heparan sulfate (HS) cofactor- or Klotho coreceptor-assisted manner.  The accumulated wealth of structural and biophys. data in the past decade has transformed our understanding of the mechanism of FGF signaling in human health and development, and has provided novel concepts in receptor tyrosine kinase (RTK) signaling.  Among these contributions are the elucidation of HS-assisted receptor dimerization, delineation of the mol. determinants of ligand-receptor specificity, tyrosine kinase regulation, receptor cis-autoinhibition, and tyrosine trans-autophosphorylation.  These structural studies have also revealed how disease-assocd. mutations highjack the physiol. mechanisms of FGFR regulation to contribute to human diseases.  In this paper, we will discuss the structurally and biophys. derived mechanisms of FGF signaling, and how the insights gained may guide the development of therapies for treatment of a diverse array of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgm8xoYjsaC7Vg90H21EOLACvtfcHk0lgeNLlyyotysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslejtL%252FK&md5=40e4706e0241ea0709c3317ebde7e816</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a015958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a015958%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DA.%2BA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520of%2520fibroblast%2520growth%2520factor%2520signaling%2520in%2520physiology%2520and%2520pathology%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2013%26volume%3D5%26issue%3D6%26spage%3Da015958%26doi%3D10.1101%2Fcshperspect.a015958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beenken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&issue=3&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26issue%3D3%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&issue=2&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lgeNLlyyotysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Touat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ileana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postel-Vinay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Targeting FGFR Signaling in Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2684</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&issue=12&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andreauthor=J.+C.+Soria&title=Targeting+FGFR+Signaling+in+Cancer&doi=10.1158%2F1078-0432.CCR-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0livGS-ybnNDkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520FGFR%2520Signaling%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.CCR-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman-Censits, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Noll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galsky, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medioni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortazavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorin, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations</span> <span class="citation_source-journal">J. Oncol. Clin</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">1, Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">4517</span><span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.4517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2FJCO.2016.34.15_suppl.4517" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4517&issue=1%2C+Suppl.&author=S.+K.+Palauthor=J.+E.+Rosenbergauthor=B.+Keamauthor=J.+Wolfauthor=R.+Bergerauthor=C.+Dittrichauthor=J.+H.+Hoffman-Censitsauthor=D.+Quinnauthor=R.+van+der+Nollauthor=H.+A.+Burrisauthor=M.+D.+Galskyauthor=G.+Gravisauthor=J.-L.+Leeauthor=J.+Medioniauthor=A.+Mortazaviauthor=P.+Marotoauthor=K.+Parkerauthor=X.+Chenauthor=R.+Isaacsauthor=D.+F.+Bajorin&title=Efficacy+of+BGJ398%2C+a+fibroblast+growth+factor+receptor+%28FGFR%29+1-3+inhibitor%2C+in+patients+%28pts%29+with+previously+treated+advanced%2Fmetastatic+urothelial+carcinoma+%28mUC%29+with+FGFR3+alterations&doi=10.1200%2FJCO.2016.34.15_suppl.4517"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.4517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.4517%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DDittrich%26aufirst%3DC.%26aulast%3DHoffman-Censits%26aufirst%3DJ.%2BH.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DGravis%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.-L.%26aulast%3DMedioni%26aufirst%3DJ.%26aulast%3DMortazavi%26aufirst%3DA.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DParker%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DBajorin%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520BGJ398%252C%2520a%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%25201-3%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520previously%2520treated%2520advanced%252Fmetastatic%2520urothelial%2520carcinoma%2520%2528mUC%2529%2520with%2520FGFR3%2520alterations%26jtitle%3DJ.%2520Oncol.%2520Clin%26date%3D2016%26volume%3D34%26issue%3D1%252C%2520Suppl%26spage%3D4517%26doi%3D10.1200%2FJCO.2016.34.15_suppl.4517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahleda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienstmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Italiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platero, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuyckens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee-Kishore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddareddigari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Phae I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">30</span><span class="NLM_x">) </span> <span class="NLM_fpage">3401</span><span class="NLM_x">–</span> <span class="NLM_lpage">3408</span><span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&issue=30&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzahauthor=B.+Zhongauthor=S.+J.+Plateroauthor=J.+W.+Smitauthor=K.+Stuyckensauthor=M.+Chatterjee-Kishoreauthor=J.+Rodonauthor=V.+Peddareddigariauthor=F.+R.+Luoauthor=J.+C.+Soria&title=Phae+I+Dose-Escalation+Study+of+JNJ-42756493%2C+an+Oral+Pan-Fibroblast+Growth+Factor+Receptor+Inhibitor%2C+in+Patients+With+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0livGS-ybnNDkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DStuyckens%26aufirst%3DK.%26aulast%3DChatterjee-Kishore%26aufirst%3DM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DPhae%2520I%2520Dose-Escalation%2520Study%2520of%2520JNJ-42756493%252C%2520an%2520Oral%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D30%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Noll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockman, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">8 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">LB-145</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-LB-145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1538-7445.AM2013-LB-145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=LB-145&issue=8+Suppl.&author=F.+Andreauthor=M.+Ransonauthor=E.+Deanauthor=A.+Vargaauthor=R.+van+der+Nollauthor=P.+K.+Stockmanauthor=D.+Ghiorghiuauthor=E.+Kilgourauthor=P.+D.+Smithauthor=M.+Macphersonauthor=P.+Lawrenceauthor=A.+Hastieauthor=J.+H.+Schellens&title=Abstract+LB-145%3A+Results+of+a+phase+I+study+of+AZD4547%2C+an+inhibitor+of+fibroblast+growth+factor+receptor+%28FGFR%29%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2013-LB-145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-LB-145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-LB-145%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DStockman%26aufirst%3DP.%2BK.%26aulast%3DGhiorghiu%26aufirst%3DD.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DMacpherson%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DP.%26aulast%3DHastie%26aufirst%3DA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DAbstract%2520LB-145%253A%2520Results%2520of%2520a%2520phase%2520I%2520study%2520of%2520AZD4547%252C%2520an%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D8%2520Suppl%26spage%3DLB-145%26doi%3D10.1158%2F1538-7445.AM2013-LB-145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Javle, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shroff, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borad, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Khoueiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarulla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGarry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekaii-Saab, T. S.</span><span> </span><span class="NLM_article-title">A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">4, Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">335</span><span class="refDoi"> DOI: 10.1200/jco.2016.34.4_suppl.335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2Fjco.2016.34.4_suppl.335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=335&issue=4%2C+Suppl.&author=M.+M.+Javleauthor=R.+T.+Shroffauthor=A.+Zhuauthor=S.+Sadeghiauthor=S.+Chooauthor=M.+J.+Boradauthor=M.+A.+Loweryauthor=A.+El-Khoueiryauthor=T.+Macarullaauthor=P.+A.+Philipauthor=D.-Y.+Ohauthor=E.+Van+Cutsemauthor=K.-H.+Yehauthor=R.+Isaacsauthor=C.+McGarryauthor=S.+Senauthor=T.+S.+Bekaii-Saab&title=A+phase+2+study+of+BGJ398+in+patients+%28pts%29+with+advanced+or+metastatic+FGFR-altered+cholangiocarcinoma+%28CCA%29+who+failed+or+are+intolerant+to+platinum-based+chemotherapy&doi=10.1200%2Fjco.2016.34.4_suppl.335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2Fjco.2016.34.4_suppl.335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2016.34.4_suppl.335%26sid%3Dliteratum%253Aachs%26aulast%3DJavle%26aufirst%3DM.%2BM.%26aulast%3DShroff%26aufirst%3DR.%2BT.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChoo%26aufirst%3DS.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DLowery%26aufirst%3DM.%2BA.%26aulast%3DEl-Khoueiry%26aufirst%3DA.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DPhilip%26aufirst%3DP.%2BA.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DK.-H.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DMcGarry%26aufirst%3DC.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DBekaii-Saab%26aufirst%3DT.%2BS.%26atitle%3DA%2520phase%25202%2520study%2520of%2520BGJ398%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520or%2520metastatic%2520FGFR-altered%2520cholangiocarcinoma%2520%2528CCA%2529%2520who%2520failed%2520or%2520are%2520intolerant%2520to%2520platinum-based%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D4%252C%2520Suppl%26spage%3D335%26doi%3D10.1200%2Fjco.2016.34.4_suppl.335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span><span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&issue=2&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+A+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520A%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D2%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&issue=4&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D4%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gavine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&issue=8&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+An+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520An%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus Porta, D.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&issue=20&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D20%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonneveld, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadtmauer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Yehuda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reece, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San-Miguel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladé, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenagh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boral, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">2487</span><span class="NLM_x">–</span> <span class="NLM_lpage">2498</span><span class="refDoi"> DOI: 10.1056/NEJMoa043445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1056%2FNEJMoa043445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=15958804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2487-2498&issue=24&author=P.+G.+Richardsonauthor=P.+Sonneveldauthor=M.+W.+Schusterauthor=D.+Irwinauthor=E.+A.+Stadtmauerauthor=T.+Faconauthor=J.-L.+Harousseauauthor=D.+Ben-Yehudaauthor=S.+Lonialauthor=H.+Goldschmidtauthor=D.+Reeceauthor=J.+F.+San-Miguelauthor=J.+Blad%C3%A9author=M.+Boccadoroauthor=J.+Cavenaghauthor=W.+S.+Daltonauthor=A.+L.+Boralauthor=D.+L.+Esseltineauthor=J.+B.+Porterauthor=D.+Schenkeinauthor=K.+C.+Anderson&title=Bortezomib+or+High-Dose+Dexamethasone+for+Relapsed+Multiple+Myeloma&doi=10.1056%2FNEJMoa043445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W.; Irwin, David; Stadtmauer, Edward A.; Facon, Thierry; Harousseau, Jean-Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; San-Miguel, Jesus F.; Blade, Joan; Boccadoro, Mario; Cavenaugh, Jamie; Dalton, William S.; Boral, Anthony L.; Esseltine, Dixie L.; Porter, Jane B.; Schenkein, David; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2487-2498</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study compared bortezomib with high-dose dexamethasone in patients with re- lapsed multiple myeloma who had received one to three previous therapies.  We randomly assigned 669 patients with relapsed myeloma to receive either an i.v. bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through' 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles.  Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression.  Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone.  The combined complete and partial response rates were 38 % for bortezomib and 18 % for dexamethasone (P < 0.001), and the complete response rates were 6 % and less than 1 %, resp. (P < 0.001).  Median times to progression in the bortezomib and dexamethasone groups were 6.22 mo (189 days) and 3.49 mo (106 days), resp. (hazard ratio, 0.55; P < 0.001).  The one-year survival rate was 80 % among patients taking bortezomib and 66 % among patients taking dexamethasone (P = 0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P = 0.001).  Grade 3 or 4 adverse events were reported in 75 % of patients treated with bortezomib and in 60 % of those treated with dexamethasone.  Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlMw95MftsqLVg90H21EOLACvtfcHk0liIq3VW1Sb1mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D&md5=d277c662178e725f9f88aa6a7e1187f2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043445%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DSchuster%26aufirst%3DM.%2BW.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHarousseau%26aufirst%3DJ.-L.%26aulast%3DBen-Yehuda%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DBoral%26aufirst%3DA.%2BL.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BB.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBortezomib%2520or%2520High-Dose%2520Dexamethasone%2520for%2520Relapsed%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D24%26spage%3D2487%26epage%3D2498%26doi%3D10.1056%2FNEJMoa043445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues Pereira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&issue=2&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0liIq3VW1Sb1mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26issue%3D2%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshua, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesvizky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oriol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosinol, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suvorov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pika, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goranova-Marinova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillenwater, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimopoulos, M. A.</span><span> </span><span class="NLM_article-title">Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1038/leu.2016.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fleu.2016.186" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=115-122&issue=1&author=P.+Moreauauthor=D.+Joshuaauthor=W.+J.+Chngauthor=A.+Palumboauthor=H.+Goldschmidtauthor=R.+Hajekauthor=T.+Faconauthor=H.+Ludwigauthor=L.+Pourauthor=R.+Niesvizkyauthor=A.+Oriolauthor=L.+Rosinolauthor=A.+Suvorovauthor=G.+Gaidanoauthor=T.+Pikaauthor=K.+Weiselauthor=V.+Goranova-Marinovaauthor=H.+H.+Gillenwaterauthor=N.+Mohamedauthor=S.+Aggarwalauthor=S.+Fengauthor=M.+A.+Dimopoulos&title=Impact+of+prior+treatment+on+patients+with+relapsed+multiple+myeloma+treated+with+carfilzomib+and+dexamethasone+vs+bortezomib+and+dexamethasone+in+the+phase+3+ENDEAVOR+study&doi=10.1038%2Fleu.2016.186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.186%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DJoshua%26aufirst%3DD.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DHajek%26aufirst%3DR.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DOriol%26aufirst%3DA.%26aulast%3DRosinol%26aufirst%3DL.%26aulast%3DSuvorov%26aufirst%3DA.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DPika%26aufirst%3DT.%26aulast%3DWeisel%26aufirst%3DK.%26aulast%3DGoranova-Marinova%26aufirst%3DV.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DMohamed%26aufirst%3DN.%26aulast%3DAggarwal%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26atitle%3DImpact%2520of%2520prior%2520treatment%2520on%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%2520treated%2520with%2520carfilzomib%2520and%2520dexamethasone%2520vs%2520bortezomib%2520and%2520dexamethasone%2520in%2520the%2520phase%25203%2520ENDEAVOR%2520study%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D1%26spage%3D115%26epage%3D122%26doi%3D10.1038%2Fleu.2016.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&issue=5&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+Zhouauthor=W.+C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+A+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0ljqKZBbZ32Rkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26issue%3D5%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: Balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+Balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljqKZBbZ32Rkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520Balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&issue=5&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lhOL4suktDNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D5%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2303</span><span class="refDoi"> DOI: 10.1021/jm970367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2296-2303&issue=15&author=J.+M.+Hambyauthor=C.+J.+Connollyauthor=M.+C.+Schroederauthor=R.+T.+Wintersauthor=H.+D.+Showalterauthor=R.+L.+Panekauthor=T.+C.+Majorauthor=B.+Olsewskiauthor=M.+J.+Ryanauthor=T.+Dahringauthor=G.+H.+Luauthor=J.+Keiserauthor=A.+Amarauthor=C.+Shenauthor=A.+J.+Krakerauthor=V.+Slintakauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=L.+Bradfordauthor=H.+Hallakauthor=A.+M.+Doherty&title=Structure-activity+relationships+for+a+novel+series+of+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm970367n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm970367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970367n%26sid%3Dliteratum%253Aachs%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DOlsewski%26aufirst%3DB.%26aulast%3DRyan%26aufirst%3DM.%2BJ.%26aulast%3DDahring%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKeiser%26aufirst%3DJ.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBradford%26aufirst%3DL.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DStructure-activity%2520relationships%2520for%2520a%2520novel%2520series%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26issue%3D15%26spage%3D2296%26epage%3D2303%26doi%3D10.1021%2Fjm970367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliseenkova, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5896</span><span class="NLM_x">–</span> <span class="NLM_lpage">5904</span><span class="refDoi"> DOI: 10.1093/emboj/17.20.5896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&issue=20&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain&doi=10.1093%2Femboj%2F17.20.5896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26issue%3D20%26spage%3D5896%26epage%3D5904%26doi%3D10.1093%2Femboj%2F17.20.5896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klohs, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkampf, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3276</span><span class="NLM_x">–</span> <span class="NLM_lpage">3292</span><span class="refDoi"> DOI: 10.1021/jm9802259</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9802259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3276-3292&issue=17&author=S.+R.+Klutchkoauthor=J.+M.+Hambyauthor=D.+H.+Boschelliauthor=Z.+Wuauthor=A.+J.+Krakerauthor=A.+M.+Amarauthor=B.+G.+Hartlauthor=C.+Shenauthor=W.+D.+Klohsauthor=R.+W.+Steinkampfauthor=D.+L.+Driscollauthor=J.+M.+Nelsonauthor=W.+L.+Elliottauthor=B.+J.+Robertsauthor=C.+L.+Stonerauthor=P.+W.+Vincentauthor=D.+J.+Dykesauthor=R.+L.+Panekauthor=G.+H.+Luauthor=T.+C.+Majorauthor=T.+K.+Dahringauthor=H.+Hallakauthor=L.+A.+Bradfordauthor=H.+D.+Showalterauthor=A.+M.+Doherty&title=2-Substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-ones.+Structure-activity+relationships+against+selected+tyrosine+kinases+and+in+vitro+and+in+vivo+anticancer+activity&doi=10.1021%2Fjm9802259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm9802259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802259%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDykes%26aufirst%3DD.%2BJ.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DBradford%26aufirst%3DL.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3D2-Substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-ones.%2520Structure-activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D17%26spage%3D3276%26epage%3D3292%26doi%3D10.1021%2Fjm9802259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&issue=3&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0ljrN7-5zgh11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D3%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&issue=7&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0ljrN7-5zgh11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D7%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljrN7-5zgh11Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behenna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho-Schultz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemkens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson-Fisher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafontaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walls, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span> </span><span class="NLM_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyr imidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&issue=5&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyr+imidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+Potent%2C+WT+Sparing%2C+Irreversible+Inhibitor+of+T790M-Containing+EGFR+Mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyr%2520imidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520Potent%252C%2520WT%2520Sparing%252C%2520Irreversible%2520Inhibitor%2520of%2520T790M-Containing%2520EGFR%2520Mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Eglen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisine, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roby, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouleau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielefeld, M.</span><span> </span><span class="NLM_article-title">The use of AlphaScreen technology in HTS: Current status</span> <span class="citation_source-journal">Curr. Chem. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.2174/1875397300801010002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.2174%2F1875397300801010002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20161822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=2-10&author=R.+M.+Eglenauthor=T.+Reisineauthor=P.+Robyauthor=N.+Rouleauauthor=C.+Illyauthor=R.+Bosseauthor=M.+Bielefeld&title=The+use+of+AlphaScreen+technology+in+HTS%3A+Current+status&doi=10.2174%2F1875397300801010002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of AlphaScreen technology in HTS: Current status</span></div><div class="casAuthors">Eglen, Richard M.; Reisine, Terry; Roby, Philippe; Rouleau, Nathalie; Illy, Chantal; Bosse, Roger; Bielefeld, Martina</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technol. developed to measuring analytes using a homogeneous protocol.  This technol. is an example of a bead-based proximity assay and was developed from a diagnostic assay technol. known as LOCI (Luminescent Oxygen Channeling Assay).  Here, singlet oxygen mols., generated by high energy irradn. of Donor beads, travel over a constrained distance (approx. 200 nm) to Acceptor beads.  This results in excitation of a cascading series of chem. reactions, ultimately causing generation of a chemiluminescent signal.  In the past decade, a wide variety of applications has been reported, ranging from detection of analytes involved in cell signaling, including protein:protein, protein:peptide, protein:small mol. or peptide:peptide interactions.  Numerous homogeneous HTS-optimized assays have been reported using the approach, including generation of second messengers (such as accumulation of cAMP, cyclic GMP, inositol [1, 4, 5] trisphosphate or phosphorylated ERK) from liganded GPCRs or tyrosine kinase receptors, post-translational modification of proteins (such as proteolytic cleavage, phosphorylation, ubiquitination and sumoylation) as well as protein-protein and protein-nucleic acid interactions.  Recently, the basic AlphaScreen technol. was extended in that the chem. of the Acceptor bead was modified such that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biol. fluid matrixes (such as trace hemolysis in serum and plasma).  In this format, referred to as AlphaLISA, it provides an alternative technol. to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.  Collectively, AlphaScreen and AlphaLISA technologies provide a facile assay platform with which one can quantitate complex cellular processes using simple no-wash microtiter plate based assays.  They provide the means by which large compd. libraries can be screened in a high throughput fashion at a diverse range of therapeutically important targets, often not readily undertaken using other homogeneous assay technologies.  This review assesses the current status of the technol. in drug discovery, in general, and high throughput screening (HTS), in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4coo45wvUbbVg90H21EOLACvtfcHk0lgu4SmrKIUp1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D&md5=4d35f83091184d6eb4d1b76444754707</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1875397300801010002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300801010002%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%2BM.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DRoby%26aufirst%3DP.%26aulast%3DRouleau%26aufirst%3DN.%26aulast%3DIlly%26aufirst%3DC.%26aulast%3DBosse%26aufirst%3DR.%26aulast%3DBielefeld%26aufirst%3DM.%26atitle%3DThe%2520use%2520of%2520AlphaScreen%2520technology%2520in%2520HTS%253A%2520Current%2520status%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F1875397300801010002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&issue=23&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+computational+methods+for+the+characterization+of+covalent+reactive+groups+for+the+prospective+design+of+irreversible+inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lgu4SmrKIUp1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520computational%2520methods%2520for%2520the%2520characterization%2520of%2520covalent%2520reactive%2520groups%2520for%2520the%2520prospective%2520design%2520of%2520irreversible%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoon, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crean, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">4628</span><span class="NLM_x">–</span> <span class="NLM_lpage">4653</span><span class="refDoi"> DOI: 10.1021/jm0500931</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500931" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4628-4653&issue=14&author=A.+M.+Thompsonauthor=A.+M.+Delaneyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=T.+A.+Spoonauthor=S.+M.+Creanauthor=H.+D.+Showalterauthor=W.+A.+Denny&title=Synthesis+and+structure-activity+relationships+of+soluble+7-substituted+3-%283%2C5-dimethoxyphenyl%29-1%2C6-naphthyridin-2-amines+and+related+ureas+as+dual+inhibitors+of+the+fibroblast+growth+factor+receptor-1+and+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinases&doi=10.1021%2Fjm0500931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0500931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500931%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DSpoon%26aufirst%3DT.%2BA.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520soluble%25207-substituted%25203-%25283%252C5-dimethoxyphenyl%2529-1%252C6-naphthyridin-2-amines%2520and%2520related%2520ureas%2520as%2520dual%2520inhibitors%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor-1%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D14%26spage%3D4628%26epage%3D4653%26doi%3D10.1021%2Fjm0500931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Thomas, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattachar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchingham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocharski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surendran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A.</span><span> </span><span class="NLM_article-title">The road map to oral bioavailability: An industrial perspective</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span><span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&issue=4&author=V.+H.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+road+map+to+oral+bioavailability%3A+An+industrial+perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0ljp1_34ENfh0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520road%2520map%2520to%2520oral%2520bioavailability%253A%2520An%2520industrial%2520perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D4%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Naven, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantesaria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadanaciva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span> </span><span class="NLM_article-title">High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds</span> <span class="citation_source-journal">Toxicol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1039/c3tx50027f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1039%2Fc3tx50027f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1eltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=235-244&issue=4&author=R.+T.+Navenauthor=S.+Kantesariaauthor=S.+Nadanacivaauthor=T.+Schroeterauthor=K.+L.+Leach&title=High+throughput+glutathione+and+Nrf2+assays+to+assess+chemical+and+biological+reactivity+of+cysteine-reactive+compounds&doi=10.1039%2Fc3tx50027f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds</span></div><div class="casAuthors">Naven, Russell T.; Kantesaria, Sheila; Nadanaciva, Sashi; Schroeter, Thomas; Leach, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Compds. that inhibit their target through covalent binding offer a no. of unique advantages as potential therapeutic agents.  They can achieve high ligand efficiency, and thus high potency, which can translate into a reduced drug dosage.  In addn., covalent binding can result in a long duration of action of the compd. and thus less frequent drug dosing.  Despite these advantages, there are several safety concerns about this class of compds. because of their inherent reactivity and potential for non-specific binding to cellular proteins.  The primary aim of this study was to establish the thiol reactivity of acrylamides and other cysteine-reactive groups by measuring reactivity against various cysteine-contg. cellular components.  Compds. were incubated with glutathione, bovine serum albumen (BSA) or human liver microsomes (HLM), and the redn. in thiol levels was quantitated using Ellman's reagent.  In addn., the ability of compds. to induce Nrf2 activity in a reporter gene assay was used as a functional readout of compd. reactivity.  The assays were validated using known thiol-reactive compds. and Nrf2 inducers such as sulforaphane (SFP) and 1,2-dithiole-3-thione (D3T).  Our results demonstrate that acrylamides possess low reactivity unless activated by electron-withdrawing N-substituents.  Analogous propynamides and vinyl sulfones were more reactive than acrylamides with respect to glutathione activity but were less reactive in the Nrf2 assay.  Large drug-like mols., including irreversible kinase inhibitors targeting BTK and EGFR, were far less reactive than their lower mol. wt. counterparts, suggesting that the presence of an electrophile is not sufficient to predict thiol reactivity.  These studies demonstrate the utility of multiple thiol sources in addn. to glutathione when assessing the thiol reactivity of covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1pd3UtswXrVg90H21EOLACvtfcHk0ljp1_34ENfh0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1eltrc%253D&md5=be2974d8bd6bf30061099b7e4ccf3c9a</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1039%2Fc3tx50027f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3tx50027f%26sid%3Dliteratum%253Aachs%26aulast%3DNaven%26aufirst%3DR.%2BT.%26aulast%3DKantesaria%26aufirst%3DS.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSchroeter%26aufirst%3DT.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26atitle%3DHigh%2520throughput%2520glutathione%2520and%2520Nrf2%2520assays%2520to%2520assess%2520chemical%2520and%2520biological%2520reactivity%2520of%2520cysteine-reactive%2520compounds%26jtitle%3DToxicol.%2520Res.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D235%26epage%3D244%26doi%3D10.1039%2Fc3tx50027f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&issue=17&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Shibata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&issue=3&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0lj9MSGmVtQSKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D3%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewdney, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arzeno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingenheimer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Fargue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWeeney, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Pablo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttman, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjogren, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecic, H.</span><span> </span><span class="NLM_article-title">Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-p yrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]py rimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38alpha mitogen-activated protein kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2255</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1021/jm101423y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101423y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2255-2265&issue=7&author=D.+M.+Goldsteinauthor=M.+Sothauthor=T.+Gabrielauthor=N.+Dewdneyauthor=A.+Kuglstatterauthor=H.+Arzenoauthor=J.+Chenauthor=W.+Bingenheimerauthor=S.+A.+Dalrympleauthor=J.+Dunnauthor=R.+Farrellauthor=S.+Frauchigerauthor=J.+La+Fargueauthor=M.+Ghateauthor=B.+Gravesauthor=R.+J.+Hillauthor=F.+Liauthor=R.+Litmanauthor=B.+Loeauthor=J.+McIntoshauthor=D.+McWeeneyauthor=E.+Pappauthor=J.+Parkauthor=H.+F.+Reeseauthor=R.+T.+Robertsauthor=D.+Rotsteinauthor=B.+San+Pabloauthor=K.+Sarmaauthor=M.+Stahlauthor=M.+L.+Sungauthor=R.+T.+Suttmanauthor=E.+B.+Sjogrenauthor=Y.+Tanauthor=A.+Trejoauthor=M.+Welchauthor=P.+Wellerauthor=B.+R.+Wongauthor=H.+Zecic&title=Discovery+of+6-%282%2C4-difluorophenoxy%29-2-%5B3-hydroxy-1-%282-hydroxyethyl%29propylamino%5D-8-methyl-8H-p+yrido%5B2%2C3-d%5Dpyrimidin-7-one+%28pamapimod%29+and+6-%282%2C4-difluorophenoxy%29-8-methyl-2-%28tetrahydro-2H-pyran-4-ylamino%29pyrido%5B2%2C3-d%5Dpy+rimidin-7%288H%29-one+%28R1487%29+as+orally+bioavailable+and+highly+selective+inhibitors+of+p38alpha+mitogen-activated+protein+kinase&doi=10.1021%2Fjm101423y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm101423y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101423y%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DArzeno%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBingenheimer%26aufirst%3DW.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DDunn%26aufirst%3DJ.%26aulast%3DFarrell%26aufirst%3DR.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DLa%2BFargue%26aufirst%3DJ.%26aulast%3DGhate%26aufirst%3DM.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DLoe%26aufirst%3DB.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DMcWeeney%26aufirst%3DD.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DReese%26aufirst%3DH.%2BF.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DRotstein%26aufirst%3DD.%26aulast%3DSan%2BPablo%26aufirst%3DB.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DSung%26aufirst%3DM.%2BL.%26aulast%3DSuttman%26aufirst%3DR.%2BT.%26aulast%3DSjogren%26aufirst%3DE.%2BB.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTrejo%26aufirst%3DA.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DZecic%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-difluorophenoxy%2529-2-%255B3-hydroxy-1-%25282-hydroxyethyl%2529propylamino%255D-8-methyl-8H-p%2520yrido%255B2%252C3-d%255Dpyrimidin-7-one%2520%2528pamapimod%2529%2520and%25206-%25282%252C4-difluorophenoxy%2529-8-methyl-2-%2528tetrahydro-2H-pyran-4-ylamino%2529pyrido%255B2%252C3-d%255Dpy%2520rimidin-7%25288H%2529-one%2520%2528R1487%2529%2520as%2520orally%2520bioavailable%2520and%2520highly%2520selective%2520inhibitors%2520of%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D7%26spage%3D2255%26epage%3D2265%26doi%3D10.1021%2Fjm101423y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Lui, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berardi, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleisher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1002/jps.2600750313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1002%2Fjps.2600750313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1986&pages=271-274&issue=3&author=C.+Y.+Luiauthor=G.+L.+Amidonauthor=R.+R.+Berardiauthor=D.+Fleisherauthor=C.+Youngbergauthor=J.+B.+Dressman&title=Comparison+of+gastrointestinal+pH+in+dogs+and+humans%3A+Implications+on+the+use+of+the+beagle+dog+as+a+model+for+oral+absorption+in+humans&doi=10.1002%2Fjps.2600750313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600750313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600750313%26sid%3Dliteratum%253Aachs%26aulast%3DLui%26aufirst%3DC.%2BY.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26aulast%3DBerardi%26aufirst%3DR.%2BR.%26aulast%3DFleisher%26aufirst%3DD.%26aulast%3DYoungberg%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DComparison%2520of%2520gastrointestinal%2520pH%2520in%2520dogs%2520and%2520humans%253A%2520Implications%2520on%2520the%2520use%2520of%2520the%2520beagle%2520dog%2520as%2520a%2520model%2520for%2520oral%2520absorption%2520in%2520humans%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1986%26volume%3D75%26issue%3D3%26spage%3D271%26epage%3D274%26doi%3D10.1002%2Fjps.2600750313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Akabane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramura, T.</span><span> </span><span class="NLM_article-title">A comparison of pharmacokinetics between humans and monkeys</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1124/dmd.109.028829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.109.028829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=308-316&issue=2&author=T.+Akabaneauthor=K.+Tabataauthor=K.+Kadonoauthor=S.+Sakudaauthor=S.+Terashitaauthor=T.+Teramura&title=A+comparison+of+pharmacokinetics+between+humans+and+monkeys&doi=10.1124%2Fdmd.109.028829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028829%26sid%3Dliteratum%253Aachs%26aulast%3DAkabane%26aufirst%3DT.%26aulast%3DTabata%26aufirst%3DK.%26aulast%3DKadono%26aufirst%3DK.%26aulast%3DSakuda%26aufirst%3DS.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DTeramura%26aufirst%3DT.%26atitle%3DA%2520comparison%2520of%2520pharmacokinetics%2520between%2520humans%2520and%2520monkeys%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D2%26spage%3D308%26epage%3D316%26doi%3D10.1124%2Fdmd.109.028829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, A.</span><span> </span><span class="NLM_article-title">Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1275</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1124/dmd.106.013037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.106.013037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1275-1284&issue=8&author=T.+Nishimuraauthor=N.+Amanoauthor=Y.+Kuboauthor=M.+Onoauthor=Y.+Katoauthor=H.+Fujitaauthor=Y.+Kimuraauthor=A.+Tsuji&title=Asymmetric+intestinal+first-pass+metabolism+causes+minimal+oral+bioavailability+of+midazolam+in+cynomolgus+monkey&doi=10.1124%2Fdmd.106.013037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.013037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.013037%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DKubo%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DA.%26atitle%3DAsymmetric%2520intestinal%2520first-pass%2520metabolism%2520causes%2520minimal%2520oral%2520bioavailability%2520of%2520midazolam%2520in%2520cynomolgus%2520monkey%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26issue%3D8%26spage%3D1275%26epage%3D1284%26doi%3D10.1124%2Fdmd.106.013037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Brown, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziano, M. J.</span><span> </span><span class="NLM_article-title">Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span><span class="refDoi"> DOI: 10.1080/01926230590961845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1080%2F01926230590961845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16036862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksVejsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=449-455&issue=4&author=A.+P.+Brownauthor=C.+L.+Courtneyauthor=L.+M.+Kingauthor=S.+C.+Groomauthor=M.+J.+Graziano&title=Cartilage+dysplasia+and+tissue+mineralization+in+the+rat+following+administration+of+a+FGF+receptor+tyrosine+kinase+inhibitor&doi=10.1080%2F01926230590961845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Brown, Alan P.; Courtney, Cynthia L.; King, Lena M.; Groom, Stephen C.; Graziano, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-455</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">PD176067 is a reversible and selective inhibitor of fibroblast growth factor receptor tyrosine kinase, and was in preclin. development as an angiogenesis inhibitor for the treatment of solid tumors.  A 14-day oral toxicity study of PD176067 in young female rats (7 wk old) was conducted at doses of 2.5, 5, and 10 mg/kg/day (15, 30, and 60 mg/m2, resp.).  Skeletal changes, and vascular and soft tissue mineralization were obsd. as primary drug-related toxicities.  To det. if these changes are specific to young, rapidly growing animals with increased vascular and osseous development, PD176067 was administered to mature (11 mo old) rats.  Female rats received PD176067 by gavage for 14 days at doses of 2.5, 5, and 10 mg/kg/day and necropsied on day 15.  Clin. signs of toxicity were seen at =5 mg/kg and one death occurred at 10 mg/kg.  Physeal dysplasia (distal femur, proximal tibia, sternum) occurred in all drug-treated animals and was characterized by dose-related increased thickness of the zones of chondrocyte proliferation and hypertrophy, and marked thickening of the zone of ossification.  Cartilage hyperplasia was characterized by proliferation of chondrocytes along margins of the synchondrosis and subperiosteum of sternebrae.  Serum phosphorus levels increased 47% and 166% at 5 and 10 mg/kg, resp.  Mineralization of cardiac myocytes, aorta, various arteries, renal tubules, and gastric mucosa and muscularis was seen at 10 mg/kg, and consistent with the presence of calcium-phosphorus deposition.  Physeal changes occurred at similar plasma PD176067 exposures in young and mature rats (AUC ≥ 4.83 μg · hr/mL).  PD176067 produced morphol. similar lesions in young and adult rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD0pKRiPrBbVg90H21EOLACvtfcHk0lhVAjkEciRwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksVejsLc%253D&md5=eadc8d4ca7aac980db8bfc149021cd9d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F01926230590961845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01926230590961845%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BP.%26aulast%3DCourtney%26aufirst%3DC.%2BL.%26aulast%3DKing%26aufirst%3DL.%2BM.%26aulast%3DGroom%26aufirst%3DS.%2BC.%26aulast%3DGraziano%26aufirst%3DM.%2BJ.%26atitle%3DCartilage%2520dysplasia%2520and%2520tissue%2520mineralization%2520in%2520the%2520rat%2520following%2520administration%2520of%2520a%2520FGF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2005%26volume%3D33%26issue%3D4%26spage%3D449%26epage%3D455%26doi%3D10.1080%2F01926230590961845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Hierro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1053%2Fj.seminoncol.2015.09.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26615127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=801-819&issue=6&author=C.+Hierroauthor=J.+Rodonauthor=J.+Tabernero&title=Fibroblast+Growth+Factor+%28FGF%29+Receptor%2FFGF+Inhibitors%3A+Novel+Targets+and+Strategies+for+Optimization+of+Response+of+Solid+Tumors&doi=10.1053%2Fj.seminoncol.2015.09.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors</span></div><div class="casAuthors">Hierro, Cinta; Rodon, Jordi; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">801-819</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) pathway plays a major role in several biol. processes, from organogenesis to metab. homeostasis and angiogenesis.  Several aberrations, including gene amplifications, point mutations, and chromosomal translocations have been described across solid tumors.  Most of these mol. alterations promote multiple steps of carcinogenesis in FGFR oncogene-addicted cells, increasing cell proliferation, angiogenesis, and drug resistance.  Data suggest that upregulation of FGFR signaling is a common event in many cancer types.  The FGFR pathway thus arises as a potential promising target for cancer treatment.  Several FGFR inhibitors are currently under development.  Initial preclin. results have translated into limited successful clin. responses when first-generation, nonspecific FGFR inhibitors were evaluated in patients.  The future development of selective and unselective FGFR inhibitors will rely on a better understanding of the tissue-specific role of FGFR signaling and identification of biomarkers to select those patients who will benefit the most from these drugs.  Further studies are warranted to establish the predictive significance of the different FGFR-aberrations and to incorporate them into clin. algorithms, now that second-generation, selective FGFR inhibitors exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNHv_T2hq8bVg90H21EOLACvtfcHk0lhVAjkEciRwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksL7F&md5=b1b150e2f8a903aab696070b71a9247c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DFibroblast%2520Growth%2520Factor%2520%2528FGF%2529%2520Receptor%252FFGF%2520Inhibitors%253A%2520Novel%2520Targets%2520and%2520Strategies%2520for%2520Optimization%2520of%2520Response%2520of%2520Solid%2520Tumors%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26issue%3D6%26spage%3D801%26epage%3D819%26doi%3D10.1053%2Fj.seminoncol.2015.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Piha-Paul, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hierro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitting, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourlay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venetsanakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric-Bernstam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">TPS2616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=TPS2616&issue=Suppl.&author=S.+A.+Piha-Paulauthor=C.+Hierroauthor=V.+Boniauthor=V.+Morenoauthor=N.+M.+Hahnauthor=R.+L.+Bittingauthor=T.+M.+Bauerauthor=R.+R.+Aggarwalauthor=S.+Gourlayauthor=P.+Smithauthor=E.+Venetsanakosauthor=F.+Meric-Bernstamauthor=K.+Brameldauthor=D.+Karrauthor=J.+Tabernero&title=A+phase+1%2C+multicenter%2C+dose-escalation+study+of+PRN1371%2C+an+irreversible+covalent+FGFR1-4+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumors%2C+followed+by+expansion+cohorts+in+patients+with+FGFR+genetic+alterations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DHahn%26aufirst%3DN.%2BM.%26aulast%3DBitting%26aufirst%3DR.%2BL.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DAggarwal%26aufirst%3DR.%2BR.%26aulast%3DGourlay%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DBrameld%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DA%2520phase%25201%252C%2520multicenter%252C%2520dose-escalation%2520study%2520of%2520PRN1371%252C%2520an%2520irreversible%2520covalent%2520FGFR1-4%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%252C%2520followed%2520by%2520expansion%2520cohorts%2520in%2520patients%2520with%2520FGFR%2520genetic%2520alterations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%26spage%3DTPS2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laederich, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degnin, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunstrum, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, W. A.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: Implications for therapeutic manipulation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">19597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1074/jbc.M110.206151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1074%2Fjbc.M110.206151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=19597-604&issue=22&author=M.+B.+Laederichauthor=C.+R.+Degninauthor=G.+P.+Lunstrumauthor=P.+Holdenauthor=W.+A.+Horton&title=Fibroblast+growth+factor+receptor+3+%28FGFR3%29+is+a+strong+heat+shock+protein+90+%28Hsp90%29+client%3A+Implications+for+therapeutic+manipulation&doi=10.1074%2Fjbc.M110.206151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206151%26sid%3Dliteratum%253Aachs%26aulast%3DLaederich%26aufirst%3DM.%2BB.%26aulast%3DDegnin%26aufirst%3DC.%2BR.%26aulast%3DLunstrum%26aufirst%3DG.%2BP.%26aulast%3DHolden%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DW.%2BA.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%25203%2520%2528FGFR3%2529%2520is%2520a%2520strong%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520client%253A%2520Implications%2520for%2520therapeutic%2520manipulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D22%26spage%3D19597%26epage%3D604%26doi%3D10.1074%2Fjbc.M110.206151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Doherty, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beynon, R. J.</span><span> </span><span class="NLM_article-title">Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1021/pr800641v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr800641v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSnur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=104-12&issue=1&author=M.+K.+Dohertyauthor=D.+E.+Hammondauthor=M.+J.+Clagueauthor=S.+J.+Gaskellauthor=R.+J.+Beynon&title=Turnover+of+the+human+proteome%3A+determination+of+protein+intracellular+stability+by+dynamic+SILAC&doi=10.1021%2Fpr800641v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Turnover of the Human Proteome: Determination of Protein Intracellular Stability by Dynamic SILAC</span></div><div class="casAuthors">Doherty, Mary K.; Hammond, Dean E.; Clague, Michael J.; Gaskell, Simon J.; Beynon, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-112</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteome of any system is a dynamic entity, such that the intracellular concn. of a protein is dictated by the relative rates of synthesis and degrdn.  In this work, the authors have analyzed time-dependent changes in the incorporation of a stable amino acid resolved precursor, a protocol the authors refer to as "dynamic SILAC", using 1-D gel sepn. followed by in-gel digestion and LC-MS/MS analyses to profile the intracellular stability of almost 600 proteins from human A549 adenocarcinoma cells, requiring multiple measures of the extent of labeling with stable isotope labeled amino acids in a classic label-chase expt.  As turnover rates are acquired, a profile can be built up that allows exploration of the 'dynamic proteome' and of putative features that predispose a protein to a high or a low rate of turnover.  Moreover, measurement of the turnover rate of individual components of supramol. complexes provides a unique insight in processes of protein complex assembly and turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT7J0-t6ZsFrVg90H21EOLACvtfcHk0ljth08e8MWuNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSnur7L&md5=ef6c25416203a513da22fd74e4353f1f</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fpr800641v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr800641v%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DM.%2BK.%26aulast%3DHammond%26aufirst%3DD.%2BE.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DGaskell%26aufirst%3DS.%2BJ.%26aulast%3DBeynon%26aufirst%3DR.%2BJ.%26atitle%3DTurnover%2520of%2520the%2520human%2520proteome%253A%2520determination%2520of%2520protein%2520intracellular%2520stability%2520by%2520dynamic%2520SILAC%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2009%26volume%3D8%26issue%3D1%26spage%3D104%26epage%3D12%26doi%3D10.1021%2Fpr800641v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Brameld, K. A.; Verner, E.</span><span> </span><span class="NLM_article-title">Quinolone Derivatives as Fibroblast Growth Factor Inhibitors</span>. PCT Int. Appl. WO 2014182829,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+A.+Brameld&author=E.+Verner&title=Quinolone+Derivatives+as+Fibroblast+Growth+Factor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26atitle%3DQuinolone%2520Derivatives%2520as%2520Fibroblast%2520Growth%2520Factor%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Verner, E.; Brameld, K. A.</span><span> </span><span class="NLM_article-title">Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors</span>. PCT Int. Appl. WO 2015120049,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+Verner&author=K.+A.+Brameld&title=Quinolone+Derivatives+as+Fibroblast+Growth+Factor+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVerner%26aufirst%3DE.%26atitle%3DQuinolone%2520Derivatives%2520as%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 48 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yujiao Wei, Yanting Tang, Yunyun Zhou, Yuyu Yang, Yetong Cui, Xuan Wang, Yubo Wang, Yulin Liu, Ning Liu, Qianqian Wang, Chong Li, Hao Ruan, Honggang Zhou, Mingming Wei, Guang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Cheng Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of a Novel 2H-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9078-9099. <a href="https://doi.org/10.1021/acs.jmedchem.1c00174" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00174%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252Ba%252BNovel%252B2H-Pyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BDerivative%252Bas%252Ba%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitor%26aulast%3DWei%26aufirst%3DYujiao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D31012021%26date%3D15062021%26volume%3D64%26issue%3D13%26spage%3D9078%26epage%3D9099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Milen Todorov, Pierre Nimsgern, Sebastien Ripoche, Michel Niklaus, Nicolas Warin, Van Huy Luu, Mario Madoerin, Jasmin Wirth, Diana Graus-Porta, Andreas Weiss, Michael Kiffe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Dario Sterker, Christelle Stamm, Flavia Adler, Alexandra Buhles, Heiko Schadt, Philippe Couttet, Jutta Blank, Inga Galuba, Jörg Trappe, Johannes Voshol, Nils Ostermann, Chao Zou, Jörg Berghausen, Alberto Del Rio Espinola, Wolfgang Jahnke, <span class="NLM_string-name hlFld-ContribAuthor">Pascal Furet</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12542-12573. <a href="https://doi.org/10.1021/acs.jmedchem.0c01019" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01019%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BRoblitinib%252B%252528FGF401%252529%252Bas%252Ba%252BReversible-Covalent%252BInhibitor%252Bof%252Bthe%252BKinase%252BActivity%252Bof%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B4%26aulast%3DFairhurst%26aufirst%3DRobin%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D01102020%26date%3D15092020%26volume%3D63%26issue%3D21%26spage%3D12542%26epage%3D12573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lin Wei, Wuqiang Wen, Li Rao, Yunyuan Huang, Mengting Lei, Kai Liu, Saiya Hu, Rongrong Song, Yanliang Ren, <span class="NLM_string-name hlFld-ContribAuthor">Jian Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (9)
                                     , 4388-4402. <a href="https://doi.org/10.1021/acs.jcim.9b01197" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b01197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b01197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b01197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DCov_FB3D%25253A%252BA%252BDe%252BNovo%252BCovalent%252BDrug%252BDesign%252BProtocol%252BIntegrating%252Bthe%252BBA-SAMP%252BStrategy%252Band%252BMachine-Learning-Based%252BSynthetic%252BTractability%252BEvaluation%26aulast%3DWei%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D27122019%26date%3D09042020%26date%3D01042020%26volume%3D60%26issue%3D9%26spage%3D4388%26epage%3D4402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sneha Ray, <span class="NLM_string-name hlFld-ContribAuthor">Andrew S. Murkin</span>. </span><span class="cited-content_cbyCitation_article-title">New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (52)
                                     , 5234-5244. <a href="https://doi.org/10.1021/acs.biochem.9b00293" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00293%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DNew%252BElectrophiles%252Band%252BStrategies%252Bfor%252BMechanism-Based%252Band%252BTargeted%252BCovalent%252BInhibitor%252BDesign%26aulast%3DRay%26aufirst%3DSneha%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02042019%26date%3D15042019%26date%3D24042019%26date%3D16042019%26volume%3D58%26issue%3D52%26spage%3D5234%26epage%3D5244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gaochan Wu, Tong Zhao, Dongwei Kang, Jian Zhang, Yuning Song, Vigneshwaran Namasivayam, Jacob Kongsted, Christophe Pannecouque, Erik De Clercq, Vasanthanathan Poongavanam, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Recent Strategic Advances in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9375-9414. <a href="https://doi.org/10.1021/acs.jmedchem.9b00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOverview%252Bof%252BRecent%252BStrategic%252BAdvances%252Bin%252BMedicinal%252BChemistry%26aulast%3DWu%26aufirst%3DGaochan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D28052019%26date%3D03052019%26volume%3D62%26issue%3D21%26spage%3D9375%26epage%3D9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yulan Wang, Yang Dai, Xiaowei Wu, Fei Li, Bo Liu, Chunpu Li, Qiufeng Liu, Yuanyang Zhou, Bao Wang, Mingrui Zhu, Rongrong Cui, Xiaoqin Tan, Zhaoping Xiong, Jia Liu, Minjia Tan, Yechun Xu, Meiyu Geng, Hualiang Jiang, Hong Liu, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Mingyue Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7473-7488. <a href="https://doi.org/10.1021/acs.jmedchem.9b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252Ba%252BSeries%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252BCompounds%252Bas%252Bthe%252BNovel%252BCovalent%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bby%252Bthe%252BRational%252BDrug%252BDesign%26aulast%3DWang%26aufirst%3DYulan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D09082019%26date%3D23072019%26volume%3D62%26issue%3D16%26spage%3D7473%26epage%3D7488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaojing Lin, Yuliana Yosaatmadja, Maria Kalyukina, Martin J. Middleditch, Zhen Zhang, Xiaoyun Lu, Ke Ding, Adam V. Patterson, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. Squire</span>. </span><span class="cited-content_cbyCitation_article-title">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1180-1186. <a href="https://doi.org/10.1021/acsmedchemlett.9b00196" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRotational%252BFreedom%25252C%252BSteric%252BHindrance%25252C%252Band%252BProtein%252BDynamics%252BExplain%252BBLU554%252BSelectivity%252Bfor%252Bthe%252BHinge%252BCysteine%252Bof%252BFGFR4%26aulast%3DLin%26aufirst%3DXiaojing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D03072019%26date%3D09072019%26date%3D03072019%26volume%3D10%26issue%3D8%26spage%3D1180%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Hao Chen, Adam V. Patterson, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 2905-2915. <a href="https://doi.org/10.1021/acs.jmedchem.8b01531" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01531%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFibroblast%252BGrowth%252BFactor%252BReceptor%252B4%252B%252528FGFR4%252529%252BSelective%252BInhibitors%252Bas%252BHepatocellular%252BCarcinoma%252BTherapy%25253A%252BAdvances%252Band%252BProspects%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D01102018%26date%3D16112018%26date%3D07112018%26volume%3D62%26issue%3D6%26spage%3D2905%26epage%3D2915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9085-9104. <a href="https://doi.org/10.1021/acs.jmedchem.7b01843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252B%252528FGFR%252529%252BInhibitors%26aulast%3DWang%26aufirst%3DYuming%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D16032018%26date%3D09032018%26volume%3D61%26issue%3D20%26spage%3D9085%26epage%3D9104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (29)
                                     , 16041-16047. <a href="https://doi.org/10.1002/ange.202101328" title="DOI URL">https://doi.org/10.1002/ange.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D29%26spage%3D16041%26epage%3D16047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (29)
                                     , 15905-15911. <a href="https://doi.org/10.1002/anie.202101328" title="DOI URL">https://doi.org/10.1002/anie.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D29%26spage%3D15905%26epage%3D15911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Sabreena  Safuan</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kumar</span>, <span class="hlFld-ContribAuthor ">Jimmy  Stalin</span>, <span class="hlFld-ContribAuthor ">Curzio  Ruegg</span>, <span class="hlFld-ContribAuthor ">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Anti‐angiogenic Drug Discovery Efforts To Combat Cancer. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 5689-5700. <a href="https://doi.org/10.1002/slct.202101792" title="DOI URL">https://doi.org/10.1002/slct.202101792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101792%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAnti%2525E2%252580%252590angiogenic%252BDrug%252BDiscovery%252BEfforts%252BTo%252BCombat%252BCancer%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D23%26spage%3D5689%26epage%3D5700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Nannan  Chen</span>, <span class="hlFld-ContribAuthor ">Dandan  Xia</span>, <span class="hlFld-ContribAuthor ">Shicheng  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Dai</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Tong</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Jiang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>104 </em><a href="https://doi.org/10.1016/j.chembiol.2021.03.016" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.03.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.03.016%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252Bcovalent%252Binhibitor%252Bof%252Bheat%252Bshock%252Bprotein%252B90%252Bwith%252Bantitumor%252Bactivity%252Bthat%252Bblocks%252Bthe%252Bco-chaperone%252Bbinding%252Bvia%252BC-terminal%252Bmodification%26aulast%3DLi%26aufirst%3DLi%26date%3D2021%26volume%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaowei  Wu</span>, <span class="hlFld-ContribAuthor ">Mengdi  Dai</span>, <span class="hlFld-ContribAuthor ">Rongrong  Cui</span>, <span class="hlFld-ContribAuthor ">Yulan  Wang</span>, <span class="hlFld-ContribAuthor ">Chunpu  Li</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Jihui  Zhao</span>, <span class="hlFld-ContribAuthor ">Bao  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Dan  Feng</span>, <span class="hlFld-ContribAuthor ">Tianbiao  Yang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zheng</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 781-794. <a href="https://doi.org/10.1016/j.apsb.2020.09.002" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.09.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.09.002%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bderivatives%252Bas%252Bcovalent%252BFGFR%252Binhibitors%26aulast%3DWu%26aufirst%3DXiaowei%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D781%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ikumi  Kuriwaki</span>, <span class="hlFld-ContribAuthor ">Minoru  Kameda</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Iikubo</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Hisamichi</span>, <span class="hlFld-ContribAuthor ">Yuichiro  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Shigetoshi  Kikuchi</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Moritomo</span>, <span class="hlFld-ContribAuthor ">Yutaka  Kondoh</span>, <span class="hlFld-ContribAuthor ">Tadashi  Terasaka</span>, <span class="hlFld-ContribAuthor ">Yasushi  Amano</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Tateishi</span>, <span class="hlFld-ContribAuthor ">Yuka  Echizen</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Iwai</span>, <span class="hlFld-ContribAuthor ">Atsushi  Noda</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Tomiyama</span>, <span class="hlFld-ContribAuthor ">Taisuke  Nakazawa</span>, <span class="hlFld-ContribAuthor ">Masaaki  Hirano</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>33 </em>, 116019. <a href="https://doi.org/10.1016/j.bmc.2021.116019" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bstructure-activity%252Brelationships%252Bof%252Bpyrimidine%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bactive%252BFGFR3%252Binhibitors%252Bwith%252Bboth%252Bincreased%252Bsystemic%252Bexposure%252Band%252Benhanced%252Bin%252Bvitro%252Bpotency%26aulast%3DKuriwaki%26aufirst%3DIkumi%26date%3D2021%26volume%3D33%26spage%3D116019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pratibha  Yadav</span>, <span class="hlFld-ContribAuthor ">Kamal  Shah</span>. </span><span class="cited-content_cbyCitation_article-title">An overview on synthetic and pharmaceutical prospective of pyrido[2,3‐
              d
              ]pyrimidines scaffold. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 633-648. <a href="https://doi.org/10.1111/cbdd.13800" title="DOI URL">https://doi.org/10.1111/cbdd.13800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13800%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DAn%252Boverview%252Bon%252Bsynthetic%252Band%252Bpharmaceutical%252Bprospective%252Bof%252Bpyrido%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidines%252Bscaffold%26aulast%3DYadav%26aufirst%3DPratibha%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D633%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Liang</span>, <span class="hlFld-ContribAuthor ">Juelan  Wang</span>, <span class="hlFld-ContribAuthor ">Liyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Jun  Hou</span>, <span class="hlFld-ContribAuthor ">Yonghe  Hu</span>, <span class="hlFld-ContribAuthor ">Jianyou  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of dual FGFR inhibitors as a novel therapy for cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113205. <a href="https://doi.org/10.1016/j.ejmech.2021.113205" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113205</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113205%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252Bdual%252BFGFR%252Binhibitors%252Bas%252Ba%252Bnovel%252Btherapy%252Bfor%252Bcancer%26aulast%3DLiang%26aufirst%3DQi%26date%3D2021%26volume%3D214%26spage%3D113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolu  Chen</span>, <span class="hlFld-ContribAuthor ">Yanan  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Zhang</span>, <span class="hlFld-ContribAuthor ">Daoxing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhaojun  Dong</span>, <span class="hlFld-ContribAuthor ">Chengguang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Qinqin  Xia</span>, <span class="hlFld-ContribAuthor ">Jianzhang  Wu</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113219. <a href="https://doi.org/10.1016/j.ejmech.2021.113219" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113219%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bindazole%252Bderivatives%252Bas%252Bselective%252Band%252Bpotent%252BFGFR4%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BFGF19-driven%252Bhepatocellular%252Bcancer%26aulast%3DChen%26aufirst%3DXiaolu%26date%3D2021%26volume%3D214%26spage%3D113219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-di  Dai</span>, <span class="hlFld-ContribAuthor ">Yue-liang  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Fan</span>, <span class="hlFld-ContribAuthor ">Yang  Dai</span>, <span class="hlFld-ContribAuthor ">Yin-chun  Ji</span>, <span class="hlFld-ContribAuthor ">Yi-ming  Sun</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Lan-lan  Li</span>, <span class="hlFld-ContribAuthor ">Yu-ming  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-hu  Duan</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>. </span><span class="cited-content_cbyCitation_article-title">DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.1038/s41401-020-00567-3" title="DOI URL">https://doi.org/10.1038/s41401-020-00567-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-00567-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-00567-3%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DDW14383%252Bis%252Ban%252Birreversible%252Bpan-FGFR%252Binhibitor%252Bthat%252Bsuppresses%252BFGFR-dependent%252Btumor%252Bgrowth%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DDai%26aufirst%3DMeng-di%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Sootome</span>, <span class="hlFld-ContribAuthor ">Hidenori  Fujita</span>, <span class="hlFld-ContribAuthor ">Kenjiro  Ito</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Ochiiwa</span>, <span class="hlFld-ContribAuthor ">Yayoi  Fujioka</span>, <span class="hlFld-ContribAuthor ">Kimihiro  Ito</span>, <span class="hlFld-ContribAuthor ">Akihiro  Miura</span>, <span class="hlFld-ContribAuthor ">Takeshi  Sagara</span>, <span class="hlFld-ContribAuthor ">Satoru  Ito</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Ohsawa</span>, <span class="hlFld-ContribAuthor ">Sachie  Otsuki</span>, <span class="hlFld-ContribAuthor ">Kaoru  Funabashi</span>, <span class="hlFld-ContribAuthor ">Masakazu  Yashiro</span>, <span class="hlFld-ContribAuthor ">Kenichi  Matsuo</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Yonekura</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Hirai</span>. </span><span class="cited-content_cbyCitation_article-title">Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (22)
                                     , 4986-4997. <a href="https://doi.org/10.1158/0008-5472.CAN-19-2568" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-19-2568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-19-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-19-2568%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DFutibatinib%252BIs%252Ba%252BNovel%252BIrreversible%252BFGFR%252B1%2525E2%252580%2525934%252BInhibitor%252BThat%252BShows%252BSelective%252BAntitumor%252BActivity%252Bagainst%252BFGFR-Deregulated%252BTumors%26aulast%3DSootome%26aufirst%3DHiroshi%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D22%26spage%3D4986%26epage%3D4997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin M.  Levine</span>, <span class="hlFld-ContribAuthor ">Kai  Ding</span>, <span class="hlFld-ContribAuthor ">Lyuqin  Chen</span>, <span class="hlFld-ContribAuthor ">Steffi  Oesterreich</span>. </span><span class="cited-content_cbyCitation_article-title">FGFR4: A promising therapeutic target for breast cancer and other solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>214 </em>, 107590. <a href="https://doi.org/10.1016/j.pharmthera.2020.107590" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2020.107590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2020.107590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2020.107590%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DFGFR4%25253A%252BA%252Bpromising%252Btherapeutic%252Btarget%252Bfor%252Bbreast%252Bcancer%252Band%252Bother%252Bsolid%252Btumors%26aulast%3DLevine%26aufirst%3DKevin%2BM.%26date%3D2020%26volume%3D214%26spage%3D107590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ikumi  Kuriwaki</span>, <span class="hlFld-ContribAuthor ">Minoru  Kameda</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Hisamichi</span>, <span class="hlFld-ContribAuthor ">Shigetoshi  Kikuchi</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Iikubo</span>, <span class="hlFld-ContribAuthor ">Yuichiro  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Moritomo</span>, <span class="hlFld-ContribAuthor ">Yutaka  Kondoh</span>, <span class="hlFld-ContribAuthor ">Yasushi  Amano</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Tateishi</span>, <span class="hlFld-ContribAuthor ">Yuka  Echizen</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Iwai</span>, <span class="hlFld-ContribAuthor ">Atsushi  Noda</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Tomiyama</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Masaaki  Hirano</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (10)
                                     , 115453. <a href="https://doi.org/10.1016/j.bmc.2020.115453" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115453%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdrug%252Bdesign%252Bof%252B1%25252C3%25252C5-triazine%252Band%252Bpyrimidine%252Bderivatives%252Bas%252Bnovel%252BFGFR3%252Binhibitors%252Bwith%252Bhigh%252Bselectivity%252Bover%252BVEGFR2%26aulast%3DKuriwaki%26aufirst%3DIkumi%26date%3D2020%26volume%3D28%26issue%3D10%26spage%3D115453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng-Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Nian-Guang  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Wu-Chen  Xie</span>, <span class="hlFld-ContribAuthor ">Si-Ping  Yang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Zhi-Hao  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance in the development of novel, selective and potent FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111884. <a href="https://doi.org/10.1016/j.ejmech.2019.111884" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111884%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvance%252Bin%252Bthe%252Bdevelopment%252Bof%252Bnovel%25252C%252Bselective%252Band%252Bpotent%252BFGFR%252Binhibitors%26aulast%3DLiu%26aufirst%3DFeng-Tao%26date%3D2020%26volume%3D186%26spage%3D111884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>151 </em>, 104567. <a href="https://doi.org/10.1016/j.phrs.2019.104567" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104567%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B%252528FGFR%252529%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%252Bincluding%252Bthose%252Bof%252Bthe%252Burinary%252Bbladder%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D151%26spage%3D104567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Wen</span>, <span class="hlFld-ContribAuthor ">Lina  Gao</span>, <span class="hlFld-ContribAuthor ">Liang  Gao</span>, <span class="hlFld-ContribAuthor ">Fengjun  He</span>, <span class="hlFld-ContribAuthor ">Jingxian  Zhou</span>, <span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Rupeng  Dai</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Chen</span>, <span class="hlFld-ContribAuthor ">Di  Kang</span>, <span class="hlFld-ContribAuthor ">Lihong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 1
              H
              -1,2,4-triazole, benzothiazole and indazole-based derivatives as potent FGFR1 inhibitors
              via
              fragment-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 72-84. <a href="https://doi.org/10.1080/14756366.2019.1673745" title="DOI URL">https://doi.org/10.1080/14756366.2019.1673745</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1673745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1673745%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B1%252BH%252B-1%25252C2%25252C4-triazole%25252C%252Bbenzothiazole%252Band%252Bindazole-based%252Bderivatives%252Bas%252Bpotent%252BFGFR1%252Binhibitors%252Bvia%252Bfragment-based%252Bvirtual%252Bscreening%26aulast%3DLiu%26aufirst%3DJian%26date%3D2020%26date%3D2019%26volume%3D35%26issue%3D1%26spage%3D72%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillem  Jubete</span>, <span class="hlFld-ContribAuthor ">Raimon  Puig de la Bellacasa</span>, <span class="hlFld-ContribAuthor ">Roger  Estrada-Tejedor</span>, <span class="hlFld-ContribAuthor ">Jordi  Teixidó</span>, <span class="hlFld-ContribAuthor ">José I.  Borrell</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (22)
                                     , 4161. <a href="https://doi.org/10.3390/molecules24224161" title="DOI URL">https://doi.org/10.3390/molecules24224161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24224161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24224161%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-ones%25253A%252BSynthesis%252Band%252BBiomedical%252BApplications%26aulast%3DJubete%26aufirst%3DGuillem%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Lin-jiang  Tong</span>, <span class="hlFld-ContribAuthor ">Bai-you  Tang</span>, <span class="hlFld-ContribAuthor ">Hong-yan  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xian-wen  Cao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Hong-lin  Li</span>, <span class="hlFld-ContribAuthor ">Xu-hong  Qian</span>, <span class="hlFld-ContribAuthor ">Yu-fang  Xu</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2019,</strong> <em>40 </em>
                                    (6)
                                     , 823-832. <a href="https://doi.org/10.1038/s41401-018-0191-7" title="DOI URL">https://doi.org/10.1038/s41401-018-0191-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-018-0191-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-018-0191-7%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DC11%25252C%252Ba%252Bnovel%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B1%252B%252528FGFR1%252529%252Binhibitor%25252C%252Bsuppresses%252Bbreast%252Bcancer%252Bmetastasis%252Band%252Bangiogenesis%26aulast%3DChen%26aufirst%3DZhuo%26date%3D2019%26date%3D2018%26volume%3D40%26issue%3D6%26spage%3D823%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuyan  Dai</span>, <span class="hlFld-ContribAuthor ">Zhan  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhuchu  Chen</span>, <span class="hlFld-ContribAuthor ">Guangyu  Xu</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (6)
                                     , 614. <a href="https://doi.org/10.3390/cells8060614" title="DOI URL">https://doi.org/10.3390/cells8060614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8060614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8060614%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DFibroblast%252BGrowth%252BFactor%252BReceptors%252B%252528FGFRs%252529%25253A%252BStructures%252Band%252BSmall%252BMolecule%252BInhibitors%26aulast%3DDai%26aufirst%3DShuyan%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D6%26spage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinglin  Zhang</span>, <span class="hlFld-ContribAuthor ">Patrick M. K.  Tang</span>, <span class="hlFld-ContribAuthor ">Yuhang  Zhou</span>, <span class="hlFld-ContribAuthor ">Alfred S. L.  Cheng</span>, <span class="hlFld-ContribAuthor ">Jun  Yu</span>, <span class="hlFld-ContribAuthor ">Wei  Kang</span>, <span class="hlFld-ContribAuthor ">Ka Fai  To</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (6)
                                     , 637. <a href="https://doi.org/10.3390/cells8060637" title="DOI URL">https://doi.org/10.3390/cells8060637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8060637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8060637%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTargeting%252Bthe%252BOncogenic%252BFGF-FGFR%252BAxis%252Bin%252BGastric%252BCarcinogenesis%26aulast%3DZhang%26aufirst%3DJinglin%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D6%26spage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Fu</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuyan  Dai</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Guangyu  Xu</span>, <span class="hlFld-ContribAuthor ">Zhuchu  Chen</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (42)
                                     , 5890-5893. <a href="https://doi.org/10.1039/C9CC02052G" title="DOI URL">https://doi.org/10.1039/C9CC02052G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC02052G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC02052G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCharacterization%252Bof%252BFGF401%252Bas%252Ba%252Breversible%252Bcovalent%252Binhibitor%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B4%26aulast%3DZhou%26aufirst%3DZhan%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D42%26spage%3D5890%26epage%3D5893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avick Kumar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Indranil  Samanta</span>, <span class="hlFld-ContribAuthor ">Anushree  Mondal</span>, <span class="hlFld-ContribAuthor ">Wenshe Ray  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Inhibition in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 889-906. <a href="https://doi.org/10.1002/cmdc.201900107" title="DOI URL">https://doi.org/10.1002/cmdc.201900107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900107%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCovalent%252BInhibition%252Bin%252BDrug%252BDiscovery%26aulast%3DGhosh%26aufirst%3DAvick%2BKumar%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D889%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima  Arshad</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Lalit Mohan  Nainwal</span>, <span class="hlFld-ContribAuthor ">Sumit Kumar  Kaushik</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Suhel  Parvez</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing quinquennial anticancer journey of morpholine: A SAR based review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 324-356. <a href="https://doi.org/10.1016/j.ejmech.2019.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRevealing%252Bquinquennial%252Banticancer%252Bjourney%252Bof%252Bmorpholine%25253A%252BA%252BSAR%252Bbased%252Breview%26aulast%3DArshad%26aufirst%3DFatima%26date%3D2019%26volume%3D167%26spage%3D324%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Fumarola</span>, <span class="hlFld-ContribAuthor ">Nicole  Bozza</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Francesca  Ferlenghi</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Mara  Bonelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Daniele  Cretella</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Roberta  Minari</span>, <span class="hlFld-ContribAuthor ">Maricla  Galetti</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00179" title="DOI URL">https://doi.org/10.3389/fonc.2019.00179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00179%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DExpanding%252Bthe%252BArsenal%252Bof%252BFGFR%252BInhibitors%25253A%252BA%252BNovel%252BChloroacetamide%252BDerivative%252Bas%252Ba%252BNew%252BIrreversible%252BAgent%252BWith%252BAnti-proliferative%252BActivity%252BAgainst%252BFGFR1-Amplified%252BLung%252BCancer%252BCell%252BLines%26aulast%3DFumarola%26aufirst%3DClaudia%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Kalyukina</span>, <span class="hlFld-ContribAuthor ">Yuliana  Yosaatmadja</span>, <span class="hlFld-ContribAuthor ">Martin J.  Middleditch</span>, <span class="hlFld-ContribAuthor ">Adam V.  Patterson</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Squire</span>. </span><span class="cited-content_cbyCitation_article-title">TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (4)
                                     , 494-500. <a href="https://doi.org/10.1002/cmdc.201800719" title="DOI URL">https://doi.org/10.1002/cmdc.201800719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800719%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTAS%2525E2%252580%252590120%252BCancer%252BTarget%252BBinding%25253A%252BDefining%252BReactivity%252Band%252BRevealing%252Bthe%252BFirst%252BFibroblast%252BGrowth%252BFactor%252BReceptor%2525E2%252580%2525851%252B%252528FGFR1%252529%252BIrreversible%252BStructure%26aulast%3DKalyukina%26aufirst%3DMaria%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D494%26epage%3D500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh  Badichi Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Clement  Agoni</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">The irony of chirality – unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[
              b
              ]thiophen-2-yl)-7
              H
              -pyrrolo[2,3-
              d
              ]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFR4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (5)
                                     , 1176-1190. <a href="https://doi.org/10.1039/C8OB02811G" title="DOI URL">https://doi.org/10.1039/C8OB02811G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02811G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02811G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Birony%252Bof%252Bchirality%252B%2525E2%252580%252593%252Bunveiling%252Bthe%252Bdistinct%252Bmechanistic%252Bbinding%252Band%252Bactivities%252Bof%252B1-%2525283-%2525284-amino-5-%2525287-methoxy-5-methylbenzo%25255B%252Bb%252B%25255Dthiophen-2-yl%252529-7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-7-yl%252529pyrrolidin-1-yl%252529prop-2-en-1-one%252Benantiomers%252Bas%252Birreversible%252Bcovalent%252BFGFR4%252Binhibitors%26aulast%3DBadichi%2BAkher%26aufirst%3DFarideh%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D5%26spage%3D1176%26epage%3D1190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendan  Farrell</span>, <span class="hlFld-ContribAuthor ">Alexander L.  Breeze</span>. </span><span class="cited-content_cbyCitation_article-title">Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2018,</strong> <em>46 </em>
                                    (6)
                                     , 1753-1770. <a href="https://doi.org/10.1042/BST20180004" title="DOI URL">https://doi.org/10.1042/BST20180004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20180004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20180004%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DStructure%25252C%252Bactivation%252Band%252Bdysregulation%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252Bkinases%25253A%252Bperspectives%252Bfor%252Bclinical%252Btargeting%26aulast%3DFarrell%26aufirst%3DBrendan%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D6%26spage%3D1753%26epage%3D1770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna M.  Zinchenko</span>, <span class="hlFld-ContribAuthor ">Lyubov V.  Muzychka</span>, <span class="hlFld-ContribAuthor ">Olexandr V.  Kucher</span>, <span class="hlFld-ContribAuthor ">Iryna V.  Sadkova</span>, <span class="hlFld-ContribAuthor ">Pavel K.  Mykhailiuk</span>, <span class="hlFld-ContribAuthor ">Oleg B.  Smolii</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of 6-Aminopyrido[2,3-
              d
              ]pyrimidin-7-ones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (46)
                                     , 6519-6523. <a href="https://doi.org/10.1002/ejoc.201801204" title="DOI URL">https://doi.org/10.1002/ejoc.201801204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201801204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201801204%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252B6-Aminopyrido%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-7-ones%26aulast%3DZinchenko%26aufirst%3DAnna%2BM.%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D46%26spage%3D6519%26epage%3D6523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fisayo  Olotu</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Adeniji</span>, <span class="hlFld-ContribAuthor ">Clement  Agoni</span>, <span class="hlFld-ContribAuthor ">Imane  Bjij</span>, <span class="hlFld-ContribAuthor ">Shama  Khan</span>, <span class="hlFld-ContribAuthor ">Ahmed  Elrashedy</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2018,</strong> <em>13 </em>
                                    (10)
                                     , 903-918. <a href="https://doi.org/10.1080/17460441.2018.1516035" title="DOI URL">https://doi.org/10.1080/17460441.2018.1516035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2018.1516035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2018.1516035%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Bselective%252Bheat%252Bshock%252Bprotein%252Binhibitors%252Bas%252Banti-cancer%252Btherapy%26aulast%3DOlotu%26aufirst%3DFisayo%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D10%26spage%3D903%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shama  Khan</span>, <span class="hlFld-ContribAuthor ">Imane  Bjij</span>, <span class="hlFld-ContribAuthor ">Fisayo A  Olotu</span>, <span class="hlFld-ContribAuthor ">Clement  Agoni</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Adeniji</span>, <span class="hlFld-ContribAuthor ">Mahmoud E  S Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent simulations of covalent/irreversible enzyme inhibition in drug discovery: a reliable technical protocol. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (19)
                                     , 2265-2275. <a href="https://doi.org/10.4155/fmc-2017-0304" title="DOI URL">https://doi.org/10.4155/fmc-2017-0304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0304%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bsimulations%252Bof%252Bcovalent%25252Firreversible%252Benzyme%252Binhibition%252Bin%252Bdrug%252Bdiscovery%25253A%252Ba%252Breliable%252Btechnical%252Bprotocol%26aulast%3DKhan%26aufirst%3DShama%26date%3D2018%26volume%3D10%26issue%3D19%26spage%3D2265%26epage%3D2275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingmin  Ding</span>, <span class="hlFld-ContribAuthor ">Hongbo  Wang</span>, <span class="hlFld-ContribAuthor ">Chunrong  Qu</span>, <span class="hlFld-ContribAuthor ">Fuchun  Xu</span>, <span class="hlFld-ContribAuthor ">Yingmin  Zhu</span>, <span class="hlFld-ContribAuthor ">Guangyao  Lv</span>, <span class="hlFld-ContribAuthor ">Yungang  Lu</span>, <span class="hlFld-ContribAuthor ">Qingjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Hui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Zeng</span>, <span class="hlFld-ContribAuthor ">Jingwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunhong  Yan</span>, <span class="hlFld-ContribAuthor ">Jiacheng  Lin</span>, <span class="hlFld-ContribAuthor ">Huai-Rong  Luo</span>, <span class="hlFld-ContribAuthor ">Zixing  Deng</span>, <span class="hlFld-ContribAuthor ">Yuling  Xiao</span>, <span class="hlFld-ContribAuthor ">Jinbin  Tian</span>, <span class="hlFld-ContribAuthor ">Michael X.  Zhu</span>, <span class="hlFld-ContribAuthor ">Xuechuan  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2018,</strong> <em>432 </em>, 47-55. <a href="https://doi.org/10.1016/j.canlet.2018.05.041" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.05.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.05.041%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252BTRPC6%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bgastric%252Bcancer%26aulast%3DDing%26aufirst%3DMingmin%26date%3D2018%26volume%3D432%26spage%3D47%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Jun  Xue</span>, <span class="hlFld-ContribAuthor ">Ming-Tao  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Ping  Sun</span>, <span class="hlFld-ContribAuthor ">Yu-Yan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments and advances of FGFR as a potential target in cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (17)
                                     , 2109-2126. <a href="https://doi.org/10.4155/fmc-2018-0103" title="DOI URL">https://doi.org/10.4155/fmc-2018-0103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0103%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Band%252Badvances%252Bof%252BFGFR%252Bas%252Ba%252Bpotential%252Btarget%252Bin%252Bcancer%26aulast%3DXue%26aufirst%3DWen-Jun%26date%3D2018%26volume%3D10%26issue%3D17%26spage%3D2109%26epage%3D2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleni  Venetsanakos</span>, <span class="hlFld-ContribAuthor ">Ken A.  Brameld</span>, <span class="hlFld-ContribAuthor ">Vernon T.  Phan</span>, <span class="hlFld-ContribAuthor ">Erik  Verner</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Yan  Xing</span>, <span class="hlFld-ContribAuthor ">Danny  Tam</span>, <span class="hlFld-ContribAuthor ">Jacob  LaStant</span>, <span class="hlFld-ContribAuthor ">Kwan  Leung</span>, <span class="hlFld-ContribAuthor ">Dane E.  Karr</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Hill</span>, <span class="hlFld-ContribAuthor ">Mary E.  Gerritsen</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, <span class="hlFld-ContribAuthor ">Jens Oliver  Funk</span>, <span class="hlFld-ContribAuthor ">J. Michael  Bradshaw</span>. </span><span class="cited-content_cbyCitation_article-title">The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2017,</strong> <em>16 </em>
                                    (12)
                                     , 2668-2676. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0309" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0309%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DThe%252BIrreversible%252BCovalent%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252BPRN1371%252BExhibits%252BSustained%252BInhibition%252Bof%252BFGFR%252Bafter%252BDrug%252BClearance%26aulast%3DVenetsanakos%26aufirst%3DEleni%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D12%26spage%3D2668%26epage%3D2676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0016.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Second-Generation Clinical FGFR Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural assessment of cysteine residues for covalent binding to FGFR1–4. (A) Several cysteine residues are proximal to the ATP binding pocket as illustrated by the spheres superimposed on the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a> X-ray structure. Listed for each highlighted cysteine sequence/structure location are the other kinases which share a cysteine at that position. (B) Structural alignment and overlay of three X-ray crystal structures (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI">2FGI</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQL">3GQL</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4F">3C4F</a>) of FGFR1 with different ligands occupying the ATP binding site. The highlighted cysteine residue (Cys488 in FGFR1) targeted for covalent binding by the compounds described in this work is located in the flexible glycine-rich loop and adopts a different conformation in each structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Chemical Structures of Reported FGFR Inhibitors and Irreversible Covalent Inhibitor Design Hypothesis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis of Compound <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Rat in vivo inhibition of bFGF-induced CCL2 production (black line, right <i>y</i>-axis) by a 10 mg/kg dose of compound <b>2</b> or <b>34</b> and associated compound plasma levels (gray line, left <i>y</i>-axis) at 1, 5, and 12 h postdose (<i>n</i> = 5 per group): (A) reversible compound <b>2</b>; (B) irreversible covalent compound <b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK/PD and efficacy of compound <b>34</b> in a SNU16 mouse xenograft model. (A) Western blots showing blockade of pFGFR within the tumor 8 h postdose. Lanes 1–4 are individual mice dosed with vehicle, and lanes 5–8 are individual mice dosed with compound <b>34</b> at 10 mg/kg q.d. (B) Tumor growth inhibition (TGI) dose response upon oral administration of compound <b>34</b> (<i>n</i> = 10 per dose group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/medium/jm-2017-003605_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Phase I clinical data for once daily oral administration of compound <b>34</b>. (A) Total plasma concentration over time. (B) Percent change at day 8 of serum phosphate, a pharmacodynamic marker of FGFR inhibition; the asterisk (∗) indicates prophylactic administration of phosphate binders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00360/20170804/images/large/jm-2017-003605_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00360&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Helsten, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomson, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-3212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1078-0432.CCR-14-3212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26373574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=259-267&issue=1&author=T.+Helstenauthor=S.+Elkinauthor=E.+Arthurauthor=B.+N.+Tomsonauthor=J.+Carterauthor=R.+Kurzrock&title=The+FGFR+Landscape+in+Cancer%3A+Analysis+of+4%2C853+Tumors+by+Next-Generation+Sequencing&doi=10.1158%2F1078-0432.CCR-14-3212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing</span></div><div class="casAuthors">Helsten, Teresa; Elkin, Sheryl; Arthur, Elisa; Tomson, Brett N.; Carter, Jennifer; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">259-267</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mol. profiling may have prognostic and predictive value, and is increasingly used in the clin. setting.  There are more than a dozen fibroblast growth factor receptor (FGFR) inhibitors in development.  Optimal therapeutic application of FGFR inhibitors requires knowledge of the rates and types of FGFR aberrations in a variety of cancer types.  Exptl. Design: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clin. Lab.  Improvement Amendments (CLIA) lab. (Foundation Medicine) using next-generation sequencing (182 or 236 genes), and analyzed by N-of-One.  Results: FGFR aberrations were found in 7.1% of cancers, with the majority being gene amplification (66% of the aberrations), followed by mutations (26%) and rearrangements (8%).  FGFR1 (mostly amplification) was affected in 3.5% of 4,853 patients; FGFR2 in 1.5%; FGFR3 in 2.0%; and FGFR4 in 0.5%.  Almost every type of malignancy examd. showed some patients with FGFR aberrations, but the cancers most commonly affected were urothelial (32% FGFR-aberrant); breast (18%); endometrial (∼13%), squamous lung cancers (∼13%), and ovarian cancer (∼9%).  Among 35 unique FGFR mutations seen in this dataset, all but two are found in COSMIC.  Seventeen of the 35 are known to be activating, and 11 are transforming.  Conclusions: FGFR aberrations are common in a wide variety of cancers, with the majority being gene amplifications or activating mutations.  These data suggest that FGFR inhibition could be an important therapeutic option across multiple tumor types.  Clin Cancer Res; 22(1); 259-67. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_eQBJarU4mLVg90H21EOLACvtfcHk0lht8Gas2FiqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqs7Y%253D&md5=7172cbee01331fe0d3fac5dada295fc2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-3212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-3212%26sid%3Dliteratum%253Aachs%26aulast%3DHelsten%26aufirst%3DT.%26aulast%3DElkin%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DB.%2BN.%26aulast%3DCarter%26aufirst%3DJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DThe%2520FGFR%2520Landscape%2520in%2520Cancer%253A%2520Analysis%2520of%25204%252C853%2520Tumors%2520by%2520Next-Generation%2520Sequencing%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D1%26spage%3D259%26epage%3D267%26doi%3D10.1158%2F1078-0432.CCR-14-3212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Belov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">a015958</span><span class="refDoi"> DOI: 10.1101/cshperspect.a015958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1101%2Fcshperspect.a015958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslejtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=a015958&issue=6&author=A.+A.+Belovauthor=M.+Mohammadi&title=Molecular+mechanisms+of+fibroblast+growth+factor+signaling+in+physiology+and+pathology&doi=10.1101%2Fcshperspect.a015958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology</span></div><div class="casAuthors">Belov, Artur A.; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">A015958/1-A015958/24</span>CODEN:
                <span class="NLM_cas:coden">CSHPEU</span>;
        ISSN:<span class="NLM_cas:issn">1943-0264</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) signal in a paracrine or endocrine fashion to mediate a myriad of biol. activities, ranging from issuing developmental cues, maintaining tissue homeostasis, and regulating metabolic processes.  FGFs carry out their diverse functions by binding and dimerizing FGF receptors (FGFRs) in a heparan sulfate (HS) cofactor- or Klotho coreceptor-assisted manner.  The accumulated wealth of structural and biophys. data in the past decade has transformed our understanding of the mechanism of FGF signaling in human health and development, and has provided novel concepts in receptor tyrosine kinase (RTK) signaling.  Among these contributions are the elucidation of HS-assisted receptor dimerization, delineation of the mol. determinants of ligand-receptor specificity, tyrosine kinase regulation, receptor cis-autoinhibition, and tyrosine trans-autophosphorylation.  These structural studies have also revealed how disease-assocd. mutations highjack the physiol. mechanisms of FGFR regulation to contribute to human diseases.  In this paper, we will discuss the structurally and biophys. derived mechanisms of FGF signaling, and how the insights gained may guide the development of therapies for treatment of a diverse array of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgm8xoYjsaC7Vg90H21EOLACvtfcHk0lhxxoKJKjgndA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslejtL%252FK&md5=40e4706e0241ea0709c3317ebde7e816</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a015958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a015958%26sid%3Dliteratum%253Aachs%26aulast%3DBelov%26aufirst%3DA.%2BA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520of%2520fibroblast%2520growth%2520factor%2520signaling%2520in%2520physiology%2520and%2520pathology%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2013%26volume%3D5%26issue%3D6%26spage%3Da015958%26doi%3D10.1101%2Fcshperspect.a015958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beenken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&issue=3&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26issue%3D3%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&issue=2&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lhxxoKJKjgndA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26issue%3D2%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Touat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ileana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postel-Vinay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Targeting FGFR Signaling in Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">2684</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1078-0432.CCR-14-2329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26078430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2684-2694&issue=12&author=M.+Touatauthor=E.+Ileanaauthor=S.+Postel-Vinayauthor=F.+Andreauthor=J.+C.+Soria&title=Targeting+FGFR+Signaling+in+Cancer&doi=10.1158%2F1078-0432.CCR-14-2329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FGFR Signaling in Cancer</span></div><div class="casAuthors">Touat, Mehdi; Ileana, Ecaterina; Postel-Vinay, Sophie; Andre, Fabrice; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2684-2694</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary conserved signaling cascade that regulates several basic biol. processes, including tissue development, angiogenesis, and tissue regeneration.  Substantial evidence indicates that aberrant FGFR signaling is involved in the pathogenesis of cancer.  Recent developments of deep sequencing technologies have allowed the discovery of frequent mol. alterations in components of FGFR signaling among several solid tumor types.  Moreover, compelling preclin. models have demonstrated the oncogenic potential of these aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anticancer therapies.  Recently, the field of FGFR targeting has exponentially progressed thanks to the development of novel agents inhibiting FGFs or FGFRs, which had manageable safety profiles in early-phase trials.  Promising treatment efficacy has been obsd. in different types of malignancies, particularly in tumors harboring aberrant FGFR signaling, thus offering novel therapeutic opportunities in the era of precision medicine.  The most exciting challenges now focus on selecting patients who are most likely to benefit from these agents, increasing the efficacy of therapies with the development of novel potent compds. and combination strategies, and overcoming toxicities assocd. with FGFR inhibitors.  After examn. of the basic and translational research studies that validated the oncogenic potential of aberrant FGFR signaling, this review focuses on recent data from clin. trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.  Clin Cancer Res; 21(12); 2684-94. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZpKbvUn0hrVg90H21EOLACvtfcHk0lgSvDbYSViMbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVajurfP&md5=3dbb11de3f3a7d25d3b4ccb56400fd4d</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2329%26sid%3Dliteratum%253Aachs%26aulast%3DTouat%26aufirst%3DM.%26aulast%3DIleana%26aufirst%3DE.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520FGFR%2520Signaling%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D12%26spage%3D2684%26epage%3D2694%26doi%3D10.1158%2F1078-0432.CCR-14-2329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman-Censits, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Noll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galsky, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medioni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortazavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorin, D. F.</span><span> </span><span class="NLM_article-title">Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations</span> <span class="citation_source-journal">J. Oncol. Clin</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">1, Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">4517</span><span class="refDoi"> DOI: 10.1200/JCO.2016.34.15_suppl.4517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2FJCO.2016.34.15_suppl.4517" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4517&issue=1%2C+Suppl.&author=S.+K.+Palauthor=J.+E.+Rosenbergauthor=B.+Keamauthor=J.+Wolfauthor=R.+Bergerauthor=C.+Dittrichauthor=J.+H.+Hoffman-Censitsauthor=D.+Quinnauthor=R.+van+der+Nollauthor=H.+A.+Burrisauthor=M.+D.+Galskyauthor=G.+Gravisauthor=J.-L.+Leeauthor=J.+Medioniauthor=A.+Mortazaviauthor=P.+Marotoauthor=K.+Parkerauthor=X.+Chenauthor=R.+Isaacsauthor=D.+F.+Bajorin&title=Efficacy+of+BGJ398%2C+a+fibroblast+growth+factor+receptor+%28FGFR%29+1-3+inhibitor%2C+in+patients+%28pts%29+with+previously+treated+advanced%2Fmetastatic+urothelial+carcinoma+%28mUC%29+with+FGFR3+alterations&doi=10.1200%2FJCO.2016.34.15_suppl.4517"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.34.15_suppl.4517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.34.15_suppl.4517%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DDittrich%26aufirst%3DC.%26aulast%3DHoffman-Censits%26aufirst%3DJ.%2BH.%26aulast%3DQuinn%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGalsky%26aufirst%3DM.%2BD.%26aulast%3DGravis%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DJ.-L.%26aulast%3DMedioni%26aufirst%3DJ.%26aulast%3DMortazavi%26aufirst%3DA.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DParker%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DBajorin%26aufirst%3DD.%2BF.%26atitle%3DEfficacy%2520of%2520BGJ398%252C%2520a%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%25201-3%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520previously%2520treated%2520advanced%252Fmetastatic%2520urothelial%2520carcinoma%2520%2528mUC%2529%2520with%2520FGFR3%2520alterations%26jtitle%3DJ.%2520Oncol.%2520Clin%26date%3D2016%26volume%3D34%26issue%3D1%252C%2520Suppl%26spage%3D4517%26doi%3D10.1200%2FJCO.2016.34.15_suppl.4517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahleda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienstmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Italiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platero, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuyckens, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee-Kishore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddareddigari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Phae I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">30</span><span class="NLM_x">) </span> <span class="NLM_fpage">3401</span><span class="NLM_x">–</span> <span class="NLM_lpage">3408</span><span class="refDoi"> DOI: 10.1200/JCO.2014.60.7341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2FJCO.2014.60.7341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26324363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=3401-3408&issue=30&author=J.+Taberneroauthor=R.+Bahledaauthor=R.+Dienstmannauthor=J.+R.+Infanteauthor=A.+Mitaauthor=A.+Italianoauthor=E.+Calvoauthor=V.+Morenoauthor=B.+Adamoauthor=A.+Gazzahauthor=B.+Zhongauthor=S.+J.+Plateroauthor=J.+W.+Smitauthor=K.+Stuyckensauthor=M.+Chatterjee-Kishoreauthor=J.+Rodonauthor=V.+Peddareddigariauthor=F.+R.+Luoauthor=J.+C.+Soria&title=Phae+I+Dose-Escalation+Study+of+JNJ-42756493%2C+an+Oral+Pan-Fibroblast+Growth+Factor+Receptor+Inhibitor%2C+in+Patients+With+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2014.60.7341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors</span></div><div class="casAuthors">Tabernero, Josep; Bahleda, Rastislav; Dienstmann, Rodrigo; Infante, Jeffrey R.; Mita, Alain; Italiano, Antoine; Calvo, Emiliano; Moreno, Victor; Adamo, Barbara; Gazzah, Anas; Zhong, Bob; Platero, Suso J.; Smit, Johan W.; Stuyckens, Kim; Chatterjee-Kishore, Moitreyee; Radon, Jordi; Peddareddigari, Vijay; Luo, Feng R.; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3401-3408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.  This first-in-human study evaluates the safety, pharmacokinetics, and pharmaco-dynamics and defines the recommended phase II dose (RP2D) of JNJ-42756493.  Patients and Methods: Eligible patients with advanced solid tumors received escalating doses of JNJ-42756493 from 0.5 to 12 mg administered continuously daily or JNJ-42756493 10 or 12 mg administered intermittently (7 days on/7 days off).  Results: Sixty-five patients were enrolled.  The most common treatment-emergent adverse events included hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeusia (31%).  Twenty-seven patients (42%) experi- enced grade ≥ 3 treatment-emergent adverse events, and one dose-limiting toxicity of grade 3 ALT elevation was obsd. at 12 mg daily.  Maximum-tolerated dose was not defined.  Nine milligrams daily was considered as the initial RP2D; however, tolerability was improved with intermittent schedules, and 10 mg administered on a 7-days-on/7-days-off schedule was considered the final RP2D.  Pharmacokinetics were linear, dose proportional, and predictable, with a half-life of 50 to 60 h.  Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effect, occurred in all patients starting at 4 mg daily.  Among 23 response- evaluable patients with tumor FGFR pathway alterations, four confirmed responses and one unconfirmed partial response were obsd. in patients with glioblastoma and urothelial and endometrial cancer (all with FGFR2 or FGFR3 translocations); 16 patients had stable disease.  Conclusion: JNJ-42756493 administered at 10 mg on a 7-days-on/7-days-off schedule achieved exposures at which clin. responses were obsd., demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo08TfKyvsabVg90H21EOLACvtfcHk0lh60R_oVzVX1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGrtb4%253D&md5=6d4a6b3c2f06f3d5d1a490cf9ffe44c5</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.60.7341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.60.7341%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBahleda%26aufirst%3DR.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DA.%26aulast%3DItaliano%26aufirst%3DA.%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DStuyckens%26aufirst%3DK.%26aulast%3DChatterjee-Kishore%26aufirst%3DM.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DLuo%26aufirst%3DF.%2BR.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DPhae%2520I%2520Dose-Escalation%2520Study%2520of%2520JNJ-42756493%252C%2520an%2520Oral%2520Pan-Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D30%26spage%3D3401%26epage%3D3408%26doi%3D10.1200%2FJCO.2014.60.7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Andre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Noll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockman, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">8 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">LB-145</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2013-LB-145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F1538-7445.AM2013-LB-145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=LB-145&issue=8+Suppl.&author=F.+Andreauthor=M.+Ransonauthor=E.+Deanauthor=A.+Vargaauthor=R.+van+der+Nollauthor=P.+K.+Stockmanauthor=D.+Ghiorghiuauthor=E.+Kilgourauthor=P.+D.+Smithauthor=M.+Macphersonauthor=P.+Lawrenceauthor=A.+Hastieauthor=J.+H.+Schellens&title=Abstract+LB-145%3A+Results+of+a+phase+I+study+of+AZD4547%2C+an+inhibitor+of+fibroblast+growth+factor+receptor+%28FGFR%29%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1538-7445.AM2013-LB-145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2013-LB-145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2013-LB-145%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DDean%26aufirst%3DE.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BNoll%26aufirst%3DR.%26aulast%3DStockman%26aufirst%3DP.%2BK.%26aulast%3DGhiorghiu%26aufirst%3DD.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DMacpherson%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DP.%26aulast%3DHastie%26aufirst%3DA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DAbstract%2520LB-145%253A%2520Results%2520of%2520a%2520phase%2520I%2520study%2520of%2520AZD4547%252C%2520an%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26issue%3D8%2520Suppl%26spage%3DLB-145%26doi%3D10.1158%2F1538-7445.AM2013-LB-145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Javle, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shroff, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borad, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Khoueiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarulla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGarry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekaii-Saab, T. S.</span><span> </span><span class="NLM_article-title">A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">4, Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">335</span><span class="refDoi"> DOI: 10.1200/jco.2016.34.4_suppl.335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1200%2Fjco.2016.34.4_suppl.335" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=335&issue=4%2C+Suppl.&author=M.+M.+Javleauthor=R.+T.+Shroffauthor=A.+Zhuauthor=S.+Sadeghiauthor=S.+Chooauthor=M.+J.+Boradauthor=M.+A.+Loweryauthor=A.+El-Khoueiryauthor=T.+Macarullaauthor=P.+A.+Philipauthor=D.-Y.+Ohauthor=E.+Van+Cutsemauthor=K.-H.+Yehauthor=R.+Isaacsauthor=C.+McGarryauthor=S.+Senauthor=T.+S.+Bekaii-Saab&title=A+phase+2+study+of+BGJ398+in+patients+%28pts%29+with+advanced+or+metastatic+FGFR-altered+cholangiocarcinoma+%28CCA%29+who+failed+or+are+intolerant+to+platinum-based+chemotherapy&doi=10.1200%2Fjco.2016.34.4_suppl.335"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2Fjco.2016.34.4_suppl.335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2016.34.4_suppl.335%26sid%3Dliteratum%253Aachs%26aulast%3DJavle%26aufirst%3DM.%2BM.%26aulast%3DShroff%26aufirst%3DR.%2BT.%26aulast%3DZhu%26aufirst%3DA.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DChoo%26aufirst%3DS.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DLowery%26aufirst%3DM.%2BA.%26aulast%3DEl-Khoueiry%26aufirst%3DA.%26aulast%3DMacarulla%26aufirst%3DT.%26aulast%3DPhilip%26aufirst%3DP.%2BA.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DK.-H.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DMcGarry%26aufirst%3DC.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DBekaii-Saab%26aufirst%3DT.%2BS.%26atitle%3DA%2520phase%25202%2520study%2520of%2520BGJ398%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520or%2520metastatic%2520FGFR-altered%2520cholangiocarcinoma%2520%2528CCA%2529%2520who%2520failed%2520or%2520are%2520intolerant%2520to%2520platinum-based%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26issue%3D4%252C%2520Suppl%26spage%3D335%26doi%3D10.1200%2Fjco.2016.34.4_suppl.335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span><span class="refDoi"> DOI: 10.1021/jm800790t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800790t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=278-292&issue=2&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure-activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+A+novel+class+of+receptor+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm800790t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm800790t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800790t%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure-activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520A%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D2%26spage%3D278%26epage%3D292%26doi%3D10.1021%2Fjm800790t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&issue=4&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26issue%3D4%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gavine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&issue=8&author=P.+R.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+P.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+J.+Mellorauthor=A.+N.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+An+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%2BR.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DBrooks%26aufirst%3DA.%2BN.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520An%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3D8%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus Porta, D.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&issue=20&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamino%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamino%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D20%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonneveld, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadtmauer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Yehuda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonial, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reece, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San-Miguel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bladé, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenagh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boral, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esseltine, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenkein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">2487</span><span class="NLM_x">–</span> <span class="NLM_lpage">2498</span><span class="refDoi"> DOI: 10.1056/NEJMoa043445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1056%2FNEJMoa043445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=15958804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2487-2498&issue=24&author=P.+G.+Richardsonauthor=P.+Sonneveldauthor=M.+W.+Schusterauthor=D.+Irwinauthor=E.+A.+Stadtmauerauthor=T.+Faconauthor=J.-L.+Harousseauauthor=D.+Ben-Yehudaauthor=S.+Lonialauthor=H.+Goldschmidtauthor=D.+Reeceauthor=J.+F.+San-Miguelauthor=J.+Blad%C3%A9author=M.+Boccadoroauthor=J.+Cavenaghauthor=W.+S.+Daltonauthor=A.+L.+Boralauthor=D.+L.+Esseltineauthor=J.+B.+Porterauthor=D.+Schenkeinauthor=K.+C.+Anderson&title=Bortezomib+or+High-Dose+Dexamethasone+for+Relapsed+Multiple+Myeloma&doi=10.1056%2FNEJMoa043445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bortezomib or high-dose dexamethasone for relapsed multiple myeloma</span></div><div class="casAuthors">Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W.; Irwin, David; Stadtmauer, Edward A.; Facon, Thierry; Harousseau, Jean-Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; San-Miguel, Jesus F.; Blade, Joan; Boccadoro, Mario; Cavenaugh, Jamie; Dalton, William S.; Boral, Anthony L.; Esseltine, Dixie L.; Porter, Jane B.; Schenkein, David; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2487-2498</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">This study compared bortezomib with high-dose dexamethasone in patients with re- lapsed multiple myeloma who had received one to three previous therapies.  We randomly assigned 669 patients with relapsed myeloma to receive either an i.v. bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through' 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles.  Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression.  Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone.  The combined complete and partial response rates were 38 % for bortezomib and 18 % for dexamethasone (P < 0.001), and the complete response rates were 6 % and less than 1 %, resp. (P < 0.001).  Median times to progression in the bortezomib and dexamethasone groups were 6.22 mo (189 days) and 3.49 mo (106 days), resp. (hazard ratio, 0.55; P < 0.001).  The one-year survival rate was 80 % among patients taking bortezomib and 66 % among patients taking dexamethasone (P = 0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P = 0.001).  Grade 3 or 4 adverse events were reported in 75 % of patients treated with bortezomib and in 60 % of those treated with dexamethasone.  Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlMw95MftsqLVg90H21EOLACvtfcHk0lgaXY5jTs3IrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlaksLc%253D&md5=d277c662178e725f9f88aa6a7e1187f2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043445%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSonneveld%26aufirst%3DP.%26aulast%3DSchuster%26aufirst%3DM.%2BW.%26aulast%3DIrwin%26aufirst%3DD.%26aulast%3DStadtmauer%26aufirst%3DE.%2BA.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHarousseau%26aufirst%3DJ.-L.%26aulast%3DBen-Yehuda%26aufirst%3DD.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DBoral%26aufirst%3DA.%2BL.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BB.%26aulast%3DSchenkein%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DBortezomib%2520or%2520High-Dose%2520Dexamethasone%2520for%2520Relapsed%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D24%26spage%3D2487%26epage%3D2498%26doi%3D10.1056%2FNEJMoa043445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues Pereira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&issue=2&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lisBCIyi5hDEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26issue%3D2%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshua, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldschmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesvizky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oriol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosinol, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suvorov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pika, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goranova-Marinova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillenwater, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohamed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimopoulos, M. A.</span><span> </span><span class="NLM_article-title">Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1038/leu.2016.186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fleu.2016.186" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=115-122&issue=1&author=P.+Moreauauthor=D.+Joshuaauthor=W.+J.+Chngauthor=A.+Palumboauthor=H.+Goldschmidtauthor=R.+Hajekauthor=T.+Faconauthor=H.+Ludwigauthor=L.+Pourauthor=R.+Niesvizkyauthor=A.+Oriolauthor=L.+Rosinolauthor=A.+Suvorovauthor=G.+Gaidanoauthor=T.+Pikaauthor=K.+Weiselauthor=V.+Goranova-Marinovaauthor=H.+H.+Gillenwaterauthor=N.+Mohamedauthor=S.+Aggarwalauthor=S.+Fengauthor=M.+A.+Dimopoulos&title=Impact+of+prior+treatment+on+patients+with+relapsed+multiple+myeloma+treated+with+carfilzomib+and+dexamethasone+vs+bortezomib+and+dexamethasone+in+the+phase+3+ENDEAVOR+study&doi=10.1038%2Fleu.2016.186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fleu.2016.186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2016.186%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DJoshua%26aufirst%3DD.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGoldschmidt%26aufirst%3DH.%26aulast%3DHajek%26aufirst%3DR.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DLudwig%26aufirst%3DH.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DOriol%26aufirst%3DA.%26aulast%3DRosinol%26aufirst%3DL.%26aulast%3DSuvorov%26aufirst%3DA.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DPika%26aufirst%3DT.%26aulast%3DWeisel%26aufirst%3DK.%26aulast%3DGoranova-Marinova%26aufirst%3DV.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DMohamed%26aufirst%3DN.%26aulast%3DAggarwal%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26atitle%3DImpact%2520of%2520prior%2520treatment%2520on%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%2520treated%2520with%2520carfilzomib%2520and%2520dexamethasone%2520vs%2520bortezomib%2520and%2520dexamethasone%2520in%2520the%2520phase%25203%2520ENDEAVOR%2520study%26jtitle%3DLeukemia%26date%3D2017%26volume%3D31%26issue%3D1%26spage%3D115%26epage%3D122%26doi%3D10.1038%2Fleu.2016.186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&issue=5&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+Zhouauthor=W.+C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+A+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgdno4RUKkjBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26issue%3D5%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: Balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+Balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljcJf_pFYQ_Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520Balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&issue=5&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lj6n56w4zNGPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D5%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">2296</span><span class="NLM_x">–</span> <span class="NLM_lpage">2303</span><span class="refDoi"> DOI: 10.1021/jm970367n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970367n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2296-2303&issue=15&author=J.+M.+Hambyauthor=C.+J.+Connollyauthor=M.+C.+Schroederauthor=R.+T.+Wintersauthor=H.+D.+Showalterauthor=R.+L.+Panekauthor=T.+C.+Majorauthor=B.+Olsewskiauthor=M.+J.+Ryanauthor=T.+Dahringauthor=G.+H.+Luauthor=J.+Keiserauthor=A.+Amarauthor=C.+Shenauthor=A.+J.+Krakerauthor=V.+Slintakauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=L.+Bradfordauthor=H.+Hallakauthor=A.+M.+Doherty&title=Structure-activity+relationships+for+a+novel+series+of+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors&doi=10.1021%2Fjm970367n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm970367n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970367n%26sid%3Dliteratum%253Aachs%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DOlsewski%26aufirst%3DB.%26aulast%3DRyan%26aufirst%3DM.%2BJ.%26aulast%3DDahring%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DKeiser%26aufirst%3DJ.%26aulast%3DAmar%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBradford%26aufirst%3DL.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DStructure-activity%2520relationships%2520for%2520a%2520novel%2520series%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26issue%3D15%26spage%3D2296%26epage%3D2303%26doi%3D10.1021%2Fjm970367n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliseenkova, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5896</span><span class="NLM_x">–</span> <span class="NLM_lpage">5904</span><span class="refDoi"> DOI: 10.1093/emboj/17.20.5896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1093%2Femboj%2F17.20.5896" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1998&pages=5896-5904&issue=20&author=M.+Mohammadiauthor=S.+Froumauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=R.+L.+Panekauthor=G.+H.+Luauthor=A.+V.+Eliseenkovaauthor=D.+Greenauthor=J.+Schlessingerauthor=S.+R.+Hubbard&title=Crystal+structure+of+an+angiogenesis+inhibitor+bound+to+the+FGF+receptor+tyrosine+kinase+domain&doi=10.1093%2Femboj%2F17.20.5896"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F17.20.5896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F17.20.5896%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DFroum%26aufirst%3DS.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DEliseenkova%26aufirst%3DA.%2BV.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520structure%2520of%2520an%2520angiogenesis%2520inhibitor%2520bound%2520to%2520the%2520FGF%2520receptor%2520tyrosine%2520kinase%2520domain%26jtitle%3DEMBO%2520J.%26date%3D1998%26volume%3D17%26issue%3D20%26spage%3D5896%26epage%3D5904%26doi%3D10.1093%2Femboj%2F17.20.5896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klohs, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkampf, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3276</span><span class="NLM_x">–</span> <span class="NLM_lpage">3292</span><span class="refDoi"> DOI: 10.1021/jm9802259</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9802259" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3276-3292&issue=17&author=S.+R.+Klutchkoauthor=J.+M.+Hambyauthor=D.+H.+Boschelliauthor=Z.+Wuauthor=A.+J.+Krakerauthor=A.+M.+Amarauthor=B.+G.+Hartlauthor=C.+Shenauthor=W.+D.+Klohsauthor=R.+W.+Steinkampfauthor=D.+L.+Driscollauthor=J.+M.+Nelsonauthor=W.+L.+Elliottauthor=B.+J.+Robertsauthor=C.+L.+Stonerauthor=P.+W.+Vincentauthor=D.+J.+Dykesauthor=R.+L.+Panekauthor=G.+H.+Luauthor=T.+C.+Majorauthor=T.+K.+Dahringauthor=H.+Hallakauthor=L.+A.+Bradfordauthor=H.+D.+Showalterauthor=A.+M.+Doherty&title=2-Substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7%288H%29-ones.+Structure-activity+relationships+against+selected+tyrosine+kinases+and+in+vitro+and+in+vivo+anticancer+activity&doi=10.1021%2Fjm9802259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm9802259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802259%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DKlohs%26aufirst%3DW.%2BD.%26aulast%3DSteinkampf%26aufirst%3DR.%2BW.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDykes%26aufirst%3DD.%2BJ.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DHallak%26aufirst%3DH.%26aulast%3DBradford%26aufirst%3DL.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3D2-Substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7%25288H%2529-ones.%2520Structure-activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D17%26spage%3D3276%26epage%3D3292%26doi%3D10.1021%2Fjm9802259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&issue=3&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0li0Jl5t5YqSag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D3%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&issue=7&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0lihKdWA6HYa0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D7%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&issue=4&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lihKdWA6HYa0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behenna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho-Schultz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemkens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson-Fisher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kephart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafontaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ornelas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planken, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walls, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zientek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span> </span><span class="NLM_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyr imidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&issue=5&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.+J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyr+imidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+Potent%2C+WT+Sparing%2C+Irreversible+Inhibitor+of+T790M-Containing+EGFR+Mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.%2BJ.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyr%2520imidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520Potent%252C%2520WT%2520Sparing%252C%2520Irreversible%2520Inhibitor%2520of%2520T790M-Containing%2520EGFR%2520Mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Eglen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisine, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roby, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouleau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielefeld, M.</span><span> </span><span class="NLM_article-title">The use of AlphaScreen technology in HTS: Current status</span> <span class="citation_source-journal">Curr. Chem. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.2174/1875397300801010002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.2174%2F1875397300801010002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=20161822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2008&pages=2-10&author=R.+M.+Eglenauthor=T.+Reisineauthor=P.+Robyauthor=N.+Rouleauauthor=C.+Illyauthor=R.+Bosseauthor=M.+Bielefeld&title=The+use+of+AlphaScreen+technology+in+HTS%3A+Current+status&doi=10.2174%2F1875397300801010002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of AlphaScreen technology in HTS: Current status</span></div><div class="casAuthors">Eglen, Richard M.; Reisine, Terry; Roby, Philippe; Rouleau, Nathalie; Illy, Chantal; Bosse, Roger; Bielefeld, Martina</div><div class="citationInfo"><span class="NLM_cas:title">Current Chemical Genomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-10</span>CODEN:
                <span class="NLM_cas:coden">CCGUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-3973</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) is versatile assay technol. developed to measuring analytes using a homogeneous protocol.  This technol. is an example of a bead-based proximity assay and was developed from a diagnostic assay technol. known as LOCI (Luminescent Oxygen Channeling Assay).  Here, singlet oxygen mols., generated by high energy irradn. of Donor beads, travel over a constrained distance (approx. 200 nm) to Acceptor beads.  This results in excitation of a cascading series of chem. reactions, ultimately causing generation of a chemiluminescent signal.  In the past decade, a wide variety of applications has been reported, ranging from detection of analytes involved in cell signaling, including protein:protein, protein:peptide, protein:small mol. or peptide:peptide interactions.  Numerous homogeneous HTS-optimized assays have been reported using the approach, including generation of second messengers (such as accumulation of cAMP, cyclic GMP, inositol [1, 4, 5] trisphosphate or phosphorylated ERK) from liganded GPCRs or tyrosine kinase receptors, post-translational modification of proteins (such as proteolytic cleavage, phosphorylation, ubiquitination and sumoylation) as well as protein-protein and protein-nucleic acid interactions.  Recently, the basic AlphaScreen technol. was extended in that the chem. of the Acceptor bead was modified such that emitted light is more intense and spectrally defined, thereby markedly reducing interference from biol. fluid matrixes (such as trace hemolysis in serum and plasma).  In this format, referred to as AlphaLISA, it provides an alternative technol. to classical ELISA assays and is suitable for high throughput automated fluid dispensing and detection systems.  Collectively, AlphaScreen and AlphaLISA technologies provide a facile assay platform with which one can quantitate complex cellular processes using simple no-wash microtiter plate based assays.  They provide the means by which large compd. libraries can be screened in a high throughput fashion at a diverse range of therapeutically important targets, often not readily undertaken using other homogeneous assay technologies.  This review assesses the current status of the technol. in drug discovery, in general, and high throughput screening (HTS), in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4coo45wvUbbVg90H21EOLACvtfcHk0lhs3oso3IJ30Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVWrtro%253D&md5=4d35f83091184d6eb4d1b76444754707</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1875397300801010002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1875397300801010002%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%2BM.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DRoby%26aufirst%3DP.%26aulast%3DRouleau%26aufirst%3DN.%26aulast%3DIlly%26aufirst%3DC.%26aulast%3DBosse%26aufirst%3DR.%26aulast%3DBielefeld%26aufirst%3DM.%26atitle%3DThe%2520use%2520of%2520AlphaScreen%2520technology%2520in%2520HTS%253A%2520Current%2520status%26jtitle%3DCurr.%2520Chem.%2520Genomics%26date%3D2008%26volume%3D1%26spage%3D2%26epage%3D10%26doi%3D10.2174%2F1875397300801010002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&issue=23&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+computational+methods+for+the+characterization+of+covalent+reactive+groups+for+the+prospective+design+of+irreversible+inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lhs3oso3IJ30Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520computational%2520methods%2520for%2520the%2520characterization%2520of%2520covalent%2520reactive%2520groups%2520for%2520the%2520prospective%2520design%2520of%2520irreversible%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoon, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crean, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">4628</span><span class="NLM_x">–</span> <span class="NLM_lpage">4653</span><span class="refDoi"> DOI: 10.1021/jm0500931</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0500931" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4628-4653&issue=14&author=A.+M.+Thompsonauthor=A.+M.+Delaneyauthor=J.+M.+Hambyauthor=M.+C.+Schroederauthor=T.+A.+Spoonauthor=S.+M.+Creanauthor=H.+D.+Showalterauthor=W.+A.+Denny&title=Synthesis+and+structure-activity+relationships+of+soluble+7-substituted+3-%283%2C5-dimethoxyphenyl%29-1%2C6-naphthyridin-2-amines+and+related+ureas+as+dual+inhibitors+of+the+fibroblast+growth+factor+receptor-1+and+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinases&doi=10.1021%2Fjm0500931"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm0500931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500931%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DSpoon%26aufirst%3DT.%2BA.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520soluble%25207-substituted%25203-%25283%252C5-dimethoxyphenyl%2529-1%252C6-naphthyridin-2-amines%2520and%2520related%2520ureas%2520as%2520dual%2520inhibitors%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor-1%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D14%26spage%3D4628%26epage%3D4653%26doi%3D10.1021%2Fjm0500931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Thomas, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattachar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchingham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocharski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surendran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A.</span><span> </span><span class="NLM_article-title">The road map to oral bioavailability: An industrial perspective</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">608</span><span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&issue=4&author=V.+H.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+road+map+to+oral+bioavailability%3A+An+industrial+perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0lhQezd62D98-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520road%2520map%2520to%2520oral%2520bioavailability%253A%2520An%2520industrial%2520perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26issue%3D4%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Naven, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantesaria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadanaciva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span> </span><span class="NLM_article-title">High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds</span> <span class="citation_source-journal">Toxicol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1039/c3tx50027f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1039%2Fc3tx50027f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpt1eltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=235-244&issue=4&author=R.+T.+Navenauthor=S.+Kantesariaauthor=S.+Nadanacivaauthor=T.+Schroeterauthor=K.+L.+Leach&title=High+throughput+glutathione+and+Nrf2+assays+to+assess+chemical+and+biological+reactivity+of+cysteine-reactive+compounds&doi=10.1039%2Fc3tx50027f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds</span></div><div class="casAuthors">Naven, Russell T.; Kantesaria, Sheila; Nadanaciva, Sashi; Schroeter, Thomas; Leach, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Research (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">TROEE8</span>;
        ISSN:<span class="NLM_cas:issn">2045-4538</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Compds. that inhibit their target through covalent binding offer a no. of unique advantages as potential therapeutic agents.  They can achieve high ligand efficiency, and thus high potency, which can translate into a reduced drug dosage.  In addn., covalent binding can result in a long duration of action of the compd. and thus less frequent drug dosing.  Despite these advantages, there are several safety concerns about this class of compds. because of their inherent reactivity and potential for non-specific binding to cellular proteins.  The primary aim of this study was to establish the thiol reactivity of acrylamides and other cysteine-reactive groups by measuring reactivity against various cysteine-contg. cellular components.  Compds. were incubated with glutathione, bovine serum albumen (BSA) or human liver microsomes (HLM), and the redn. in thiol levels was quantitated using Ellman's reagent.  In addn., the ability of compds. to induce Nrf2 activity in a reporter gene assay was used as a functional readout of compd. reactivity.  The assays were validated using known thiol-reactive compds. and Nrf2 inducers such as sulforaphane (SFP) and 1,2-dithiole-3-thione (D3T).  Our results demonstrate that acrylamides possess low reactivity unless activated by electron-withdrawing N-substituents.  Analogous propynamides and vinyl sulfones were more reactive than acrylamides with respect to glutathione activity but were less reactive in the Nrf2 assay.  Large drug-like mols., including irreversible kinase inhibitors targeting BTK and EGFR, were far less reactive than their lower mol. wt. counterparts, suggesting that the presence of an electrophile is not sufficient to predict thiol reactivity.  These studies demonstrate the utility of multiple thiol sources in addn. to glutathione when assessing the thiol reactivity of covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX1pd3UtswXrVg90H21EOLACvtfcHk0lhziMrIy9nR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpt1eltrc%253D&md5=be2974d8bd6bf30061099b7e4ccf3c9a</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1039%2Fc3tx50027f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3tx50027f%26sid%3Dliteratum%253Aachs%26aulast%3DNaven%26aufirst%3DR.%2BT.%26aulast%3DKantesaria%26aufirst%3DS.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSchroeter%26aufirst%3DT.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26atitle%3DHigh%2520throughput%2520glutathione%2520and%2520Nrf2%2520assays%2520to%2520assess%2520chemical%2520and%2520biological%2520reactivity%2520of%2520cysteine-reactive%2520compounds%26jtitle%3DToxicol.%2520Res.%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D235%26epage%3D244%26doi%3D10.1039%2Fc3tx50027f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&issue=17&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Shibata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span> </span><span class="NLM_article-title">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1124/dmd.114.061424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.114.061424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=25504185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=375-384&issue=3&author=Y.+Shibataauthor=M.+Chiba&title=The+role+of+extrahepatic+metabolism+in+the+pharmacokinetics+of+the+targeted+covalent+inhibitors+afatinib%2C+ibrutinib%2C+and+neratinib&doi=10.1124%2Fdmd.114.061424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib</span></div><div class="casAuthors">Shibata, Yoshihiro; Chiba, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-384, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Despite the fact that much progress has been made recently in the development of targeted covalent inhibitors (TCIs), their pharmacokinetics (PK) have not been well characterized in the light of extrahepatic clearance (CLextH) by glutathione (GSH)/glutathione S-transferase (GST)-dependent conjugation attributable to the unique electrophilic structure (e.g., acrylamide moiety) of TCI compds.  In the present study, CLextH values were examd. in rat, dog, and monkey to predict the contribution of CLextH to the PK of the TCIs afatinib, ibrutinib, and neratinib in humans.  Afatinib and neratinib both underwent extensive conjugation with GSH in buffer and cytosol fractions of liver and kidney, whereas ibrutinib showed much lower reactivity/susceptibility to GSH/GST-dependent conjugation.  The CLextH in each species was calcd. from the difference between obsd. total body clearance and predicted hepatic clearance (CLH) in cryopreserved hepatocytes suspended in 100% serum of the corresponding species.  The power-based simple allometry relating the CLextH for the unbound compd. to animal body wt. was applicable across species for afatinib and neratinib (R2 ≥ 0.9) but not for ibrutinib (R2 = 0.04).  The predicted AUC after oral administration of afatinib and neratinib agreed reasonably closely with reported values in phase I dose-escalation studies.  Comparisons of CLextH and CLH predicted that CLextH largely detd. the PK of afatinib (>90% as a proportion of total body clearance) and neratinib (∼34%) in humans.  The present method can serve as one of the tools for the optimization of PK in humans at the discovery stage for the development of TCI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquWC6d6e6DU7Vg90H21EOLACvtfcHk0lhziMrIy9nR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OmsrY%253D&md5=eaac67ce7cea5f2432c5144922ba3dd2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061424%26sid%3Dliteratum%253Aachs%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DChiba%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520extrahepatic%2520metabolism%2520in%2520the%2520pharmacokinetics%2520of%2520the%2520targeted%2520covalent%2520inhibitors%2520afatinib%252C%2520ibrutinib%252C%2520and%2520neratinib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D3%26spage%3D375%26epage%3D384%26doi%3D10.1124%2Fdmd.114.061424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewdney, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arzeno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingenheimer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Fargue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McWeeney, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Pablo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttman, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjogren, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecic, H.</span><span> </span><span class="NLM_article-title">Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-p yrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]py rimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38alpha mitogen-activated protein kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">2255</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1021/jm101423y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101423y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2255-2265&issue=7&author=D.+M.+Goldsteinauthor=M.+Sothauthor=T.+Gabrielauthor=N.+Dewdneyauthor=A.+Kuglstatterauthor=H.+Arzenoauthor=J.+Chenauthor=W.+Bingenheimerauthor=S.+A.+Dalrympleauthor=J.+Dunnauthor=R.+Farrellauthor=S.+Frauchigerauthor=J.+La+Fargueauthor=M.+Ghateauthor=B.+Gravesauthor=R.+J.+Hillauthor=F.+Liauthor=R.+Litmanauthor=B.+Loeauthor=J.+McIntoshauthor=D.+McWeeneyauthor=E.+Pappauthor=J.+Parkauthor=H.+F.+Reeseauthor=R.+T.+Robertsauthor=D.+Rotsteinauthor=B.+San+Pabloauthor=K.+Sarmaauthor=M.+Stahlauthor=M.+L.+Sungauthor=R.+T.+Suttmanauthor=E.+B.+Sjogrenauthor=Y.+Tanauthor=A.+Trejoauthor=M.+Welchauthor=P.+Wellerauthor=B.+R.+Wongauthor=H.+Zecic&title=Discovery+of+6-%282%2C4-difluorophenoxy%29-2-%5B3-hydroxy-1-%282-hydroxyethyl%29propylamino%5D-8-methyl-8H-p+yrido%5B2%2C3-d%5Dpyrimidin-7-one+%28pamapimod%29+and+6-%282%2C4-difluorophenoxy%29-8-methyl-2-%28tetrahydro-2H-pyran-4-ylamino%29pyrido%5B2%2C3-d%5Dpy+rimidin-7%288H%29-one+%28R1487%29+as+orally+bioavailable+and+highly+selective+inhibitors+of+p38alpha+mitogen-activated+protein+kinase&doi=10.1021%2Fjm101423y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm101423y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101423y%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DArzeno%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBingenheimer%26aufirst%3DW.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DDunn%26aufirst%3DJ.%26aulast%3DFarrell%26aufirst%3DR.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DLa%2BFargue%26aufirst%3DJ.%26aulast%3DGhate%26aufirst%3DM.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DLoe%26aufirst%3DB.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DMcWeeney%26aufirst%3DD.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DReese%26aufirst%3DH.%2BF.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DRotstein%26aufirst%3DD.%26aulast%3DSan%2BPablo%26aufirst%3DB.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DStahl%26aufirst%3DM.%26aulast%3DSung%26aufirst%3DM.%2BL.%26aulast%3DSuttman%26aufirst%3DR.%2BT.%26aulast%3DSjogren%26aufirst%3DE.%2BB.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTrejo%26aufirst%3DA.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DB.%2BR.%26aulast%3DZecic%26aufirst%3DH.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-difluorophenoxy%2529-2-%255B3-hydroxy-1-%25282-hydroxyethyl%2529propylamino%255D-8-methyl-8H-p%2520yrido%255B2%252C3-d%255Dpyrimidin-7-one%2520%2528pamapimod%2529%2520and%25206-%25282%252C4-difluorophenoxy%2529-8-methyl-2-%2528tetrahydro-2H-pyran-4-ylamino%2529pyrido%255B2%252C3-d%255Dpy%2520rimidin-7%25288H%2529-one%2520%2528R1487%2529%2520as%2520orally%2520bioavailable%2520and%2520highly%2520selective%2520inhibitors%2520of%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D7%26spage%3D2255%26epage%3D2265%26doi%3D10.1021%2Fjm101423y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Lui, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berardi, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleisher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1002/jps.2600750313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1002%2Fjps.2600750313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1986&pages=271-274&issue=3&author=C.+Y.+Luiauthor=G.+L.+Amidonauthor=R.+R.+Berardiauthor=D.+Fleisherauthor=C.+Youngbergauthor=J.+B.+Dressman&title=Comparison+of+gastrointestinal+pH+in+dogs+and+humans%3A+Implications+on+the+use+of+the+beagle+dog+as+a+model+for+oral+absorption+in+humans&doi=10.1002%2Fjps.2600750313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600750313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600750313%26sid%3Dliteratum%253Aachs%26aulast%3DLui%26aufirst%3DC.%2BY.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26aulast%3DBerardi%26aufirst%3DR.%2BR.%26aulast%3DFleisher%26aufirst%3DD.%26aulast%3DYoungberg%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DComparison%2520of%2520gastrointestinal%2520pH%2520in%2520dogs%2520and%2520humans%253A%2520Implications%2520on%2520the%2520use%2520of%2520the%2520beagle%2520dog%2520as%2520a%2520model%2520for%2520oral%2520absorption%2520in%2520humans%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1986%26volume%3D75%26issue%3D3%26spage%3D271%26epage%3D274%26doi%3D10.1002%2Fjps.2600750313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Akabane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadono, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teramura, T.</span><span> </span><span class="NLM_article-title">A comparison of pharmacokinetics between humans and monkeys</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1124/dmd.109.028829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.109.028829" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=308-316&issue=2&author=T.+Akabaneauthor=K.+Tabataauthor=K.+Kadonoauthor=S.+Sakudaauthor=S.+Terashitaauthor=T.+Teramura&title=A+comparison+of+pharmacokinetics+between+humans+and+monkeys&doi=10.1124%2Fdmd.109.028829"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028829%26sid%3Dliteratum%253Aachs%26aulast%3DAkabane%26aufirst%3DT.%26aulast%3DTabata%26aufirst%3DK.%26aulast%3DKadono%26aufirst%3DK.%26aulast%3DSakuda%26aufirst%3DS.%26aulast%3DTerashita%26aufirst%3DS.%26aulast%3DTeramura%26aufirst%3DT.%26atitle%3DA%2520comparison%2520of%2520pharmacokinetics%2520between%2520humans%2520and%2520monkeys%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D2%26spage%3D308%26epage%3D316%26doi%3D10.1124%2Fdmd.109.028829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nishimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, A.</span><span> </span><span class="NLM_article-title">Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1275</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1124/dmd.106.013037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1124%2Fdmd.106.013037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1275-1284&issue=8&author=T.+Nishimuraauthor=N.+Amanoauthor=Y.+Kuboauthor=M.+Onoauthor=Y.+Katoauthor=H.+Fujitaauthor=Y.+Kimuraauthor=A.+Tsuji&title=Asymmetric+intestinal+first-pass+metabolism+causes+minimal+oral+bioavailability+of+midazolam+in+cynomolgus+monkey&doi=10.1124%2Fdmd.106.013037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.013037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.013037%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DKubo%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DA.%26atitle%3DAsymmetric%2520intestinal%2520first-pass%2520metabolism%2520causes%2520minimal%2520oral%2520bioavailability%2520of%2520midazolam%2520in%2520cynomolgus%2520monkey%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26issue%3D8%26spage%3D1275%26epage%3D1284%26doi%3D10.1124%2Fdmd.106.013037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Brown, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziano, M. J.</span><span> </span><span class="NLM_article-title">Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span><span class="refDoi"> DOI: 10.1080/01926230590961845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1080%2F01926230590961845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=16036862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksVejsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=449-455&issue=4&author=A.+P.+Brownauthor=C.+L.+Courtneyauthor=L.+M.+Kingauthor=S.+C.+Groomauthor=M.+J.+Graziano&title=Cartilage+dysplasia+and+tissue+mineralization+in+the+rat+following+administration+of+a+FGF+receptor+tyrosine+kinase+inhibitor&doi=10.1080%2F01926230590961845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Brown, Alan P.; Courtney, Cynthia L.; King, Lena M.; Groom, Stephen C.; Graziano, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-455</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">PD176067 is a reversible and selective inhibitor of fibroblast growth factor receptor tyrosine kinase, and was in preclin. development as an angiogenesis inhibitor for the treatment of solid tumors.  A 14-day oral toxicity study of PD176067 in young female rats (7 wk old) was conducted at doses of 2.5, 5, and 10 mg/kg/day (15, 30, and 60 mg/m2, resp.).  Skeletal changes, and vascular and soft tissue mineralization were obsd. as primary drug-related toxicities.  To det. if these changes are specific to young, rapidly growing animals with increased vascular and osseous development, PD176067 was administered to mature (11 mo old) rats.  Female rats received PD176067 by gavage for 14 days at doses of 2.5, 5, and 10 mg/kg/day and necropsied on day 15.  Clin. signs of toxicity were seen at =5 mg/kg and one death occurred at 10 mg/kg.  Physeal dysplasia (distal femur, proximal tibia, sternum) occurred in all drug-treated animals and was characterized by dose-related increased thickness of the zones of chondrocyte proliferation and hypertrophy, and marked thickening of the zone of ossification.  Cartilage hyperplasia was characterized by proliferation of chondrocytes along margins of the synchondrosis and subperiosteum of sternebrae.  Serum phosphorus levels increased 47% and 166% at 5 and 10 mg/kg, resp.  Mineralization of cardiac myocytes, aorta, various arteries, renal tubules, and gastric mucosa and muscularis was seen at 10 mg/kg, and consistent with the presence of calcium-phosphorus deposition.  Physeal changes occurred at similar plasma PD176067 exposures in young and mature rats (AUC ≥ 4.83 μg · hr/mL).  PD176067 produced morphol. similar lesions in young and adult rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD0pKRiPrBbVg90H21EOLACvtfcHk0lgPWVLRoP7UmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksVejsLc%253D&md5=eadc8d4ca7aac980db8bfc149021cd9d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F01926230590961845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01926230590961845%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BP.%26aulast%3DCourtney%26aufirst%3DC.%2BL.%26aulast%3DKing%26aufirst%3DL.%2BM.%26aulast%3DGroom%26aufirst%3DS.%2BC.%26aulast%3DGraziano%26aufirst%3DM.%2BJ.%26atitle%3DCartilage%2520dysplasia%2520and%2520tissue%2520mineralization%2520in%2520the%2520rat%2520following%2520administration%2520of%2520a%2520FGF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2005%26volume%3D33%26issue%3D4%26spage%3D449%26epage%3D455%26doi%3D10.1080%2F01926230590961845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Hierro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1053%2Fj.seminoncol.2015.09.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=26615127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=801-819&issue=6&author=C.+Hierroauthor=J.+Rodonauthor=J.+Tabernero&title=Fibroblast+Growth+Factor+%28FGF%29+Receptor%2FFGF+Inhibitors%3A+Novel+Targets+and+Strategies+for+Optimization+of+Response+of+Solid+Tumors&doi=10.1053%2Fj.seminoncol.2015.09.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors</span></div><div class="casAuthors">Hierro, Cinta; Rodon, Jordi; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">801-819</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) pathway plays a major role in several biol. processes, from organogenesis to metab. homeostasis and angiogenesis.  Several aberrations, including gene amplifications, point mutations, and chromosomal translocations have been described across solid tumors.  Most of these mol. alterations promote multiple steps of carcinogenesis in FGFR oncogene-addicted cells, increasing cell proliferation, angiogenesis, and drug resistance.  Data suggest that upregulation of FGFR signaling is a common event in many cancer types.  The FGFR pathway thus arises as a potential promising target for cancer treatment.  Several FGFR inhibitors are currently under development.  Initial preclin. results have translated into limited successful clin. responses when first-generation, nonspecific FGFR inhibitors were evaluated in patients.  The future development of selective and unselective FGFR inhibitors will rely on a better understanding of the tissue-specific role of FGFR signaling and identification of biomarkers to select those patients who will benefit the most from these drugs.  Further studies are warranted to establish the predictive significance of the different FGFR-aberrations and to incorporate them into clin. algorithms, now that second-generation, selective FGFR inhibitors exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNHv_T2hq8bVg90H21EOLACvtfcHk0ljB7mrXcifEEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWksL7F&md5=b1b150e2f8a903aab696070b71a9247c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DFibroblast%2520Growth%2520Factor%2520%2528FGF%2529%2520Receptor%252FFGF%2520Inhibitors%253A%2520Novel%2520Targets%2520and%2520Strategies%2520for%2520Optimization%2520of%2520Response%2520of%2520Solid%2520Tumors%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26issue%3D6%26spage%3D801%26epage%3D819%26doi%3D10.1053%2Fj.seminoncol.2015.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Piha-Paul, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hierro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitting, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourlay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venetsanakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric-Bernstam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">TPS2616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=TPS2616&issue=Suppl.&author=S.+A.+Piha-Paulauthor=C.+Hierroauthor=V.+Boniauthor=V.+Morenoauthor=N.+M.+Hahnauthor=R.+L.+Bittingauthor=T.+M.+Bauerauthor=R.+R.+Aggarwalauthor=S.+Gourlayauthor=P.+Smithauthor=E.+Venetsanakosauthor=F.+Meric-Bernstamauthor=K.+Brameldauthor=D.+Karrauthor=J.+Tabernero&title=A+phase+1%2C+multicenter%2C+dose-escalation+study+of+PRN1371%2C+an+irreversible+covalent+FGFR1-4+kinase+inhibitor%2C+in+patients+with+advanced+solid+tumors%2C+followed+by+expansion+cohorts+in+patients+with+FGFR+genetic+alterations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiha-Paul%26aufirst%3DS.%2BA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DBoni%26aufirst%3DV.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DHahn%26aufirst%3DN.%2BM.%26aulast%3DBitting%26aufirst%3DR.%2BL.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DAggarwal%26aufirst%3DR.%2BR.%26aulast%3DGourlay%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DBrameld%26aufirst%3DK.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DA%2520phase%25201%252C%2520multicenter%252C%2520dose-escalation%2520study%2520of%2520PRN1371%252C%2520an%2520irreversible%2520covalent%2520FGFR1-4%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%252C%2520followed%2520by%2520expansion%2520cohorts%2520in%2520patients%2520with%2520FGFR%2520genetic%2520alterations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3DSuppl%26spage%3DTPS2616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laederich, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degnin, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunstrum, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, W. A.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: Implications for therapeutic manipulation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">19597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1074/jbc.M110.206151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=10.1074%2Fjbc.M110.206151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=19597-604&issue=22&author=M.+B.+Laederichauthor=C.+R.+Degninauthor=G.+P.+Lunstrumauthor=P.+Holdenauthor=W.+A.+Horton&title=Fibroblast+growth+factor+receptor+3+%28FGFR3%29+is+a+strong+heat+shock+protein+90+%28Hsp90%29+client%3A+Implications+for+therapeutic+manipulation&doi=10.1074%2Fjbc.M110.206151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206151%26sid%3Dliteratum%253Aachs%26aulast%3DLaederich%26aufirst%3DM.%2BB.%26aulast%3DDegnin%26aufirst%3DC.%2BR.%26aulast%3DLunstrum%26aufirst%3DG.%2BP.%26aulast%3DHolden%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DW.%2BA.%26atitle%3DFibroblast%2520growth%2520factor%2520receptor%25203%2520%2528FGFR3%2529%2520is%2520a%2520strong%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520client%253A%2520Implications%2520for%2520therapeutic%2520manipulation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D22%26spage%3D19597%26epage%3D604%26doi%3D10.1074%2Fjbc.M110.206151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Doherty, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clague, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beynon, R. J.</span><span> </span><span class="NLM_article-title">Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1021/pr800641v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr800641v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSnur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=104-12&issue=1&author=M.+K.+Dohertyauthor=D.+E.+Hammondauthor=M.+J.+Clagueauthor=S.+J.+Gaskellauthor=R.+J.+Beynon&title=Turnover+of+the+human+proteome%3A+determination+of+protein+intracellular+stability+by+dynamic+SILAC&doi=10.1021%2Fpr800641v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Turnover of the Human Proteome: Determination of Protein Intracellular Stability by Dynamic SILAC</span></div><div class="casAuthors">Doherty, Mary K.; Hammond, Dean E.; Clague, Michael J.; Gaskell, Simon J.; Beynon, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-112</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteome of any system is a dynamic entity, such that the intracellular concn. of a protein is dictated by the relative rates of synthesis and degrdn.  In this work, the authors have analyzed time-dependent changes in the incorporation of a stable amino acid resolved precursor, a protocol the authors refer to as "dynamic SILAC", using 1-D gel sepn. followed by in-gel digestion and LC-MS/MS analyses to profile the intracellular stability of almost 600 proteins from human A549 adenocarcinoma cells, requiring multiple measures of the extent of labeling with stable isotope labeled amino acids in a classic label-chase expt.  As turnover rates are acquired, a profile can be built up that allows exploration of the 'dynamic proteome' and of putative features that predispose a protein to a high or a low rate of turnover.  Moreover, measurement of the turnover rate of individual components of supramol. complexes provides a unique insight in processes of protein complex assembly and turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT7J0-t6ZsFrVg90H21EOLACvtfcHk0li8Ym2-tnDSVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSnur7L&md5=ef6c25416203a513da22fd74e4353f1f</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fpr800641v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr800641v%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DM.%2BK.%26aulast%3DHammond%26aufirst%3DD.%2BE.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26aulast%3DGaskell%26aufirst%3DS.%2BJ.%26aulast%3DBeynon%26aufirst%3DR.%2BJ.%26atitle%3DTurnover%2520of%2520the%2520human%2520proteome%253A%2520determination%2520of%2520protein%2520intracellular%2520stability%2520by%2520dynamic%2520SILAC%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2009%26volume%3D8%26issue%3D1%26spage%3D104%26epage%3D12%26doi%3D10.1021%2Fpr800641v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Brameld, K. A.; Verner, E.</span><span> </span><span class="NLM_article-title">Quinolone Derivatives as Fibroblast Growth Factor Inhibitors</span>. PCT Int. Appl. WO 2014182829,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+A.+Brameld&author=E.+Verner&title=Quinolone+Derivatives+as+Fibroblast+Growth+Factor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26atitle%3DQuinolone%2520Derivatives%2520as%2520Fibroblast%2520Growth%2520Factor%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Verner, E.; Brameld, K. A.</span><span> </span><span class="NLM_article-title">Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors</span>. PCT Int. Appl. WO 2015120049,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=E.+Verner&author=K.+A.+Brameld&title=Quinolone+Derivatives+as+Fibroblast+Growth+Factor+Receptor+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVerner%26aufirst%3DE.%26atitle%3DQuinolone%2520Derivatives%2520as%2520Fibroblast%2520Growth%2520Factor%2520Receptor%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2FGI','PDB','2FGI'); return false;">PDB: 2FGI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GQL','PDB','3GQL'); return false;">PDB: 3GQL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4F','PDB','3C4F'); return false;">PDB: 3C4F</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i27"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00360">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51750"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00360">10.1021/acs.jmedchem.7b00360</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Table S1 showing biochemical kinase inhibition profiling of compound <b>34</b> against 251 kinases (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings with FGFR1 enzyme and cellular inhibition data for compounds <b>7</b>–<b>39</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_001.pdf">jm7b00360_si_001.pdf (112.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00360/suppl_file/jm7b00360_si_002.csv">jm7b00360_si_002.csv (3.01 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00360&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00360%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-15%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00360" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b2bd68d5cd187","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
